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Abstract  
Mitochondria are essential organelles as they produce most ATP to support cellular 
activities, synthesize critical metabolic factors and are involved in lipid and phospholipid 
metabolism as well as calcium signalling. The oxidative phosphorylation (OXPHOS) system, 
present at the inner mitochondrial membrane, plays role in regulation of cellular metabolism 
and survival of cancer cells. Recent studies show importance of OXPHOS in growth of cancer 
cells via regulation of the de novo pyrimidine synthesis pathway. Dihydroorotate 
dehydrogenase (DHODH), a flavoprotein localized in the inner mitochondrial membrane, 
converts dihydroorotate (DHO) to orotate within the de novo pyrimidine synthesis pathway, 
generating electrons that are transferred, via redox-cycling of ubiquinone, to complex III 
(CIII) of respiratory chain. Since DHODH is functionally linked to CIII activity, impairment of 
respiration results in reduced activity of DHODH and pyrimidine synthesis. Therefore, 
mitochondrial damage or mutation in mitochondrial DNA (mtDNA) leads to decreased 
respiration, cancer cell proliferation and delay of tumour growth.  
As a compensation for damaged mitochondria, horizontal transfer of functional 
mitochondria from donor somatic cells to the mitochondria-damaged tumour cells was 
demonstrated. This mitochondrial renewal leads to tumour progression dependent on 
respiration recovery. In vivo transfer of mitochondria from donor cells to mtDNA-damaged 
tumour cells has been described in mouse models of melanoma and mammary tumours. It 
can be mediated by different mechanisms including extracellular microvesicles, cytoplasmic 
fusion or gap junctions. Another mechanism, described in vitro on the model of 4T1 breast 
cancer cells and B16 melanoma cells, is to transfer mitochondria through highly sensitive de 
novo formed nanotube structures between cells, representing complex networks described 
as tunnelling nanotubes (TNT).  
Using tumour cells with depleted mitochondria (rho0 cells) this work confirmed the 
essential role of mitochondrial transfer from donor cells in respiration recovery and tumour 
formation initiation. This work also clarifies the role of TNTs in the horizontal mitochondrial 
transfer as well as the properties of such way of transfer.  
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Abstrakt 
Mitochondrie jsou buněčné organely, které produkují většinu ATP nutného pro správné 
fungování řady dějů v buňce. Syntetizují důležité metabolické faktory a podílejí se na 
metabolismu lipidů a fosfolipidů, stejně jako na signalizaci vápníku. Systém oxidační 
fosforylace (OXPHOS), lokalizovaný na vnitřní mitochondriální membráně, hraje klíčovou 
roli v regulaci buněčného metabolismu a přežití nádorových buněk. Nedávné studie dokazují 
význam systému OXPHOS při růstu nádorových buněk prostřednictvím jeho propojení s de 
novo syntézou pyrimidinů.  
Enzym dihydroorotátdehydrogenáza (DHODH), flavoprotein lokalizovaný ve vnitřní 
mitochondriální membráně, přeměňuje dihydroorotát (DHO) na orotát v rámci de novo 
pyrimidinové syntézy. Tímto způsobem jsou generovány elektrony, které se přenášejí 
prostřednictvím oxidačně-redukčního koloběhu ubichinonu na komplex III (CIII) dýchacího 
řetězce. DHODH je tedy funkčně spojena s aktivitou CIII, a proto snížení schopnosti buněčné 
respirace vede ke snížení aktivity DHODH a snížené syntéze pyrimidinů. Poškození 
mitochondrií nebo mutace v mitochondriální DNA (mtDNA) mají proto za následek sníženou 
schopnost respirace, snižuje se také proliferace nádorových buněk a dochází ke zpoždění 
růstu nádoru. 
Nedávno byl však prokázán horizontální přenos funkčních mitochondrií z dárcovských 
somatických buněk do nádorových buněk s poškozenými mitochondriemi, ve kterých tak 
došlo k obnovení mitochondriálních funkcí. Tato obnova vede k progresi nádoru v závislosti 
na obnovení schopnosti buněčné respirace. In vivo byl přenos mitochondrií z dárcovských 
buněk do nádorových buněk s poškozenou mtDNA popsán na myších modelech melanomu 
a karcinomu prsu. Mitochondriální přenos může být zprostředkován různými mechanismy, 
včetně přenosu extracelulárních mikrovesikulů, cytoplazmatické fúze nebo mezerového 
spojení. Dalším mechanismem, popsaným in vitro na modelu buněk karcinomu prsu 4T1 a 
melanomových buněk B16, je přenos mitochondrií prostřednictvím vysoce citlivých 
nanotrubicových struktur tvořených de novo mezi buňkami, představujících komplexní sítě 
popsané jako tunelovací nanotrubice (TNT).  
Za použití nádorových buněk s depletovanými mitochondriemi (rho0 buněk), potvrdila tato 
práce zásadní úlohu mitochondriálního přenosu z dárcovských buněk při obnově respirace 
a vzniku nádoru. Tato práce také objasňuje úlohu TNT v horizontálním mitochondriálním 
přenosu a některé vlastnosti takového způsobu přenosu. 
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1. Introduction 
1.1. Cancer metabolism 
1.1.1. Deregulated cellular energetics as a hallmark of cancer  
Cancer occurs as a result of uncontrolled proliferation of cell accompanied by many 
transcriptional, signalling and metabolic changes. Hanahan and Weinberg proposed 
ten hallmarks of cancer depicted in Figure 1.1, which help to understand the 
development of tumours and subsequent life strategy of cancer cells. Among others, 
one of the newly formulated hallmarks of cancer is the deregulation of cellular 
energetics. (Hanahan and Weinberg 2000, Hanahan and Weinberg 2011) 
The uncontrollable growth and proliferation of cancer cells are characteristic and 
essential for all neoplastic diseases. These adjustments of life strategy of cancer cells 
require the changes in metabolism, to ensure enough fuel for emerging tumour. 
Nutrients that are used in catabolic processes to maintain cell viability, as well as in 
anabolic processes to create new biomass, are harvested by tumour cells from their 
surroundings. (Giampazolias and Tait 2016, Pavlova and Thompson 2016) 
 
FIGURE 1.1: A schematic representation of ten hallmarks of cancer.  (Hanahan and 
Weinberg 2011) 
 
For metabolism of differentiated tissues, at a standard oxygen level, the flow from 
glucose to pyruvate and from pyruvate to the final products (CO2 and H2O) is tightly 
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coupled. Under conditions of reduced oxygen supply, the lactate fermentation 
allows for reoxidation of NADH for glycolysis. In differentiated tissues the so-called 
Pasteur effect takes place, where fermentation is lower under aerobic and higher 
under anaerobic conditions. However, this effect is disturbed in tumour cells, where 
lactate production is high even in the presence of oxygen, and the coupling of 
glucose to pyruvate and pyruvate to final products generally declines. 
These abnormalities in the cancer metabolism were characterized first almost a 
century ago by Otto Warburg. In his work he described that cancer cells use 
primarily aerobic glycolysis to generate energy. Thereby the cancer cells are able to 
reprogram their metabolism and to use the process of glycolysis to synthesize 
energy in the form of adenosine triphosphate (ATP) instead of oxidative 
phosphorylation, even in the presence of sufficient oxygen. On the basis of his 
discoveries, Otto Warburg formulated the hypothesis that the primary cause of the 
onset of neoplastic diseases should be mutations in mtDNA resulting in the 
replacement of respiration by aerobic glycolysis (Koppenol, Bounds and Dang 
2011). This assumption is however valid rather under exceptional circumstances, 
when specific mitochondrial genes such as genes for succinate dehydrogenase or 
fumarate hydratase are mutated (Baysal et al. 2000, Tomlinson et al. 2002). 
Comparison of the efficiency of differentiated tissue metabolism and tumour tissue 
metabolism with respect to ATP production is represented in Figure 1.2. 
 
FIGURE 1.2: Diagram of the efficiency of differentiated tissue metabolism compared to 
tumour tissue metabolism with respect to ATP production. Figure adapted from Vander 
Heiden, Cantley and Thompson, 2009.   
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The metabolism of glucose and glutamine in normal cells is very efficient. Primary 
end products (CO2, H2O, and ammonia) are generated while the maximum yield of 
ATP per mole of glucose or glutamine is achieved. On the other hand, the metabolism 
of glucose and glutamine in tumour cells is very uneconomical. The primary end 
products are apart from CO2 and H2O, also lactate, pyruvate, alanine, and aspartate 
and there is low yield of ATP per mole of glucose or glutamine achieved in cancer 
cells.  
This evokes a question, why the ATP production through glycolysis should be more 
beneficial for cancer cells than eighteen times more efficient energy production 
through the process of oxidative phosphorylation. Reprogrammed cancer cells are 
able to divert the glycolytic metabolism intermediates into different synthetic 
pathways and thus be more effective in the production of a new biomass, i.e. in 
growth and proliferation. That’s why “Warburgian metabolism” can be found in 
highly proliferating cells including embryonic stem cells (Vander Heiden, Cantley 
and Thompson 2009, Hsu and Sabatini 2008, Kondoh et al. 2007). 
Due to anaerobic glycolysis, glucose uptake via glucose transporter GLUT1 in 
tumours is increased. This phenomenon is visualized and documented by non-
invasive positron emission tomography (PET), which is used to diagnose the 
neoplastic diseases as well as to analyse the effectiveness of its treatment. PET 
involves in administering radioactive fluorine-labelled glucose analogue (18F-
fluorodeoxyglucose, FDG) to patients, and subsequent tomographic visualization of 
sites where glucose in the body is preferentially consumed and metabolized as 
shown in Figure 1.3 (Vander Heiden et al. 2009, Som et al. 1980, Almuhaideb, 
Papathanasiou and Bomanji 2011). 
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FIGURE 1.3: Tumour visualized using positron emission tomography 18F-
fluorodeoxyglucose. Fused images of FDG-PET and computed tomography (CT) visualization 
of decreased metabolism of glucose in a patient with malignant sarcoma before and after 
therapy. Excess FDG is excreted in the urine, and therefore the kidneys (K) and bladder (B) are 
also visualized as labelled as well as the tumour (T) in the pre-therapy image [Image courtesy 
of A. D. Van den Abbeele, Dana-Farber Cancer Institute, Boston] (Vander Heiden et al. 2009). 
 
Cancer cells, due to their rapid proliferation, accumulate changes in metabolism to 
ensure a steady supply of nutrients. According to the work of Pavlova and 
Thompson, these changes can be divided into three groups shown in Figure 1.4, 
where the first group comprise changes affecting the nutrients uptake. Second and 
third group then represents re-programming of intracellular metabolism and long-
term metabolite-directed changes leading to the changes in cell functions and their 
behaviour in tumour microenvironment, respectively (Pavlova and Thompson 
2016). 
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FIGURE 1.4: Emerging hallmarks of cancer metabolism (Pavlova and Thompson 2016). 
 
1.1.2. Nutrients uptake deregulations in cancer cells   
As mentioned above, glucose and glutamine are two essential nutrients necessary 
for biosynthesis in mammalian cells. In vivo, within the progressive tumour growth, 
cancer cells are forced to deal with a lack of nutrients and oxygen induced by 
insufficient vascular supply to a growing tumour. Therefore, they have to reprogram 
themselves and increase glucose and glutamine uptake together with using the 
intermediates of glycolysis and the Krebs cycle (KC) for biosynthesis. In the absence 
of free amino acids, cancer cells are able to obtain them by micropinocytosis of 
extracellular proteins. Other possible ways of obtaining nutrients alternatively are 
living cell entosis or apoptotic body phagocytosis. The reprogramming of cancer 
cells takes place via the signalling of growth factors, which is directly affected by 
metabolism and secondary affects transcription and translation.  
 
1.1.3. Multi-functional roles of glycolytic enzymes 
Oncogenic signalization reprograms directly the enzymes of glycolysis. Hexokinase 
2, which phosphorylates glucose in the first step of glycolysis and produces glucose-
6-phosphate (G6P) was determined as a cancer’s double-edged sword (Mathupala, 
Ko and Pedersen 2006). This enzyme is usually active only during embryonic 
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development and is reactivated in tumour cells. It is capable to extensively increase 
glycolysis partially by its localization on the mitochondrial membrane, where it 
transfers ATP from the inner space of mitochondria directly from voltage anion 
dependent channel (VADC). Thanks to its location in proximity with VADC and ANT, 
HK2 prevents access of pro-apoptotic proteins and formation of the mitochondrial 
transition pore, and thus prevents apoptosis (Pastorino, Shulga and Hoek 2002, 
Majewski et al. 2004, Rathmell et al. 2003, Pastorino and Hoek 2003, Danial et al. 
2003). 
The intracellular metabolic enzyme glucose-6-phosphate isomerase (GPI) becomes 
an extracellular signalling molecule during evolution. GPI expression is induced by 
cMyc and HIF-1 and is increased in many cancers (Pusapati et al. 2016, Semenza 
2013, de Padua et al. 2017). In addition to its glycolytic function – isomerizing 
glucose-6-phosphate to fructose-6-phosphate intracellularly, it can also be secreted 
as autocrine motility factor (AMF). Upon binding to its receptor GPI, it affects the 
activity of the small GTPases Rac and Rho regulating the cytoskeleton assembly, 
which results in increased invasiveness of cancer cells (Gallardo-Pérez et al. 2014). 
GPI also directly and indirectly promotes angiogenesis in the tumour 
microenvironment and inhibits apoptosis via both MAPK and PI3K pathways 
(Yanagawa et al. 2004, Niinaka et al. 1998, Watanabe et al. 1996). 
Enolase 1 (ENO1) converts 2-phosphoglycerate to phosphoenolpyruvate and plays 
a role as a plasminogen receptor. Plasmin activator anneals to the plasmin activator 
receptor, converting plasminogen to plasmin, which in turn activates matrix 
metalloproteases and various forms of growth factors (Subramanian and Miller 
2000, Feo et al. 2000, Kumari and Malla 2015). This leads to increased motility and 
invasiveness of cancer cells. The expression of enolase is regulated at multiple levels 
– i.e. nuclear factor kappa B (NFκB) and hypoxia-inducible factor-1α (HIF-1α) are 
involved in the transcriptional activation of ENO1 and also activation of the Src and 
MEK/ERK signalling pathways upregulates the ENO1 expression. The possibility 
that other factors might regulate ENO1 expression during tumorigenesis remains to 
be investigated (Zhan et al. 2015). 
Pyruvate kinase M2 (PKM2) is a less active isoform of the terminal glycolytic 
enzyme pyruvate kinase. Its expression is increased and facilitates lactate 
production in cancer cells. Modulation of PKM2 catalytic activity also regulates the 
synthesis of DNA and lipids that are required for cell proliferation, and of NADPH 
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that is required for redox homeostasis. (Ward and Thompson 2012, Li, Zheng and 
Lu 2016, Luo and Semenza 2012, Dong et al. 2016). 
Glyceraldehyde phosphate dehydrogenase (GAPD) participates in the NAD+/NADH 
balance in the cell and also participates in transcriptional regulation and in cell 
death via the SIAH1-GAPDH cascade. Its expression is highly dependent on the 
proliferative state of the cell and can also be regulated by transcription factors, such 
as HIF-1 and p53. When cancer cells resist apoptosis, the increased level of GAPDH 
inhibits cell death by simultaneously increasing ATP levels through glycolysis and 
stimulating autophagy-mediated clearance of permeabilized mitochondria. (Colell, 
Green and Ricci 2009) 
(Dastoor and Dreyer 2001, Chuang, Hough and Senatorov 2005, Zheng, Roeder and 
Luo 2003). The enzyme lactate dehydrogenase plays key role in oxidation of NADH 
to NAD+, while reducing pyruvate to lactate. Moreover, it is also involved in 
transcriptional regulation as a component of OCA-S a trans-activator complex of 
histone H2B, whose components are associated with cancer metastasis (Zheng et al. 
2003).  
 
1.1.4. Key mutations responsible for changing metabolism of cancer cells  
To meet the requirements for rapid ATP formation, mutations of protooncogenes 
and tumour suppressor genes occur in cancer cells. The products of these mutations 
drive or regulate various signalling pathways and at least some of them act in 
mitochondria. In total, ~1.6% of the 22,000 functional genes in the human genome 
show recurrent somatic mutations in cancer (Futreal et al. 2004). Figure 1.5 depicts 
the scheme of connections between several metabolic pathways and key 
components of signalling pathways, that could be influenced or mutated within 
metabolic reprogramming in cancer cells. 
  
Activation of protooncogenes  
The most common events in the process of cancer cell transformation besides 
changes in  p53 expression, include changes in ERK, PI3K or AMPK signalling 
cascades and p53 or Myc signalling pathways (Galluzzi et al. 2010). 
The above-mentioned PI3K, Myc and HIF-1 proteins enhance the expression of 
glucose transporters and in addition with p53 increase the activity of enzymes that 
control the limiting steps of glycolysis – hexokinase (HK), phosphofructokinase, or 
lactate dehydrogenase (LDH). At the same time the association of HK with ANT and 
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VDAC attenuate the OXPHOS due the constitutive activation of PI3K-LKB1 pathway 
and inhibits ATP synthase by a sharp decrease in ADP levels that are consumed by 
substrate phosphorylation in glycolysis (Wallace 2005, Mathupala et al. 2006).  
The mammalian target of rapamycin (mTOR) signalling pathway is activated in 
cancer cells to contribute to the metabolic turnover. It affects the biosynthesis of 
lipids and proteins, mRNA translation and ribosome biogenesis. Moreover, mTOR 
plays a role of important activator of HIF1, regulating the survival of cancer cells in 
hypoxic conditions (Guertin and Sabatini 2007, LoRusso 2016). AMPK, repressing 
the mTOR signalling, is often attenuated in cancer cells to avoid subsequent stress 
responses (Shackelford and Shaw 2009).   
 
Inactivation of p53  
p53 is inactivated or mutated in more than half of neoplasms. The loss of p53 in 
tumour cells causes increased glycolysis, reduced pyruvate oxidation and decreased 
ATP production by oxidative phosphorylation. p53 inhibits aerobic glycolysis in 
several pathways (Liu et al. 2015).  Interestingly, it has been reported that mutant 
p53 proteins and wild-type p53 proteins often regulate the same cellular biological 
processes with opposite effects. The wild-type p53 activity inhibits cytochrome 
oxidase and increases production of F2,6P2, which both result in inhibition of 
glycolysis (Zheng 2012, Maddocks and Vousden 2011). It also reduces pyruvate 
dehydrogenase (PDK2) kinase expression and thereby activates the pyruvate 
dehydrogenase complex, which reduces the requirement for ATP formation during 
glycolysis (Amelio and Melino 2015). On the other hand, mutant p53 promotes 
glycolysis through distinct mechanisms. It induces the mevalonate pathway, which 
participates in a regulation of lipids metabolism. Furthermore, the mutant p53 
activates RhoA/ROCK signalling pathway that stimulates GLUT1 translocation to 
the plasmatic membrane and therefore increases glycolysis and supports the 
Warburg effect in cancer cells (Zhang et al. 2013b).  
p53 has been extensively studied in last decades and many functions of wild-type 
p53, such as cell cycle arrest, apoptosis, and senescence have been discovered. 
However, some aspects of the role of mutant p53 in cancer metabolism regulation 
remain partly unclear as well as how different forms of mutant p53 impact upon 
tumour metabolism.  Metabolic regulation of cancer cells via the p53 protein 
remains a highly dynamic area of research.  
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Activation of HIF-1  
HIF-1 is expressed in many types of neoplastic diseases mainly as a response to 
hypoxia in rapidly growing and poorly vascularized tumours. HIF-1 increases 
aerobic glycolysis and therefore supports the Warburg effect. Increased activity of 
HIF-1 induces the same effects as the loss of the p53 function, i.e. enhanced 
glycolysis and glucose uptake via increased expression of the GLUT1 transporter or 
decreased oxidation of pyruvate and ATP production in OXPHOS (Chan et al. 2011). 
HIF-1 increases expression of aldolase, enolase, PDK1 and PDK3 as well as the 
expression of LDHA and the lactate transporter MCT4, which is used as a marker of 
aerobic glycolysis in glycolytic cells (Kitajima and Miyazaki 2013, Kroemer and 
Pouyssegur 2008). 
 
FIGURE 1.5: Scheme of connection between several metabolic pathways and molecular 
mechanisms of cancer-specific metabolic reprogramming.  
α-KG (α-ketoglutarate), AcCoA (acetyl coenzyme A), AMPK (AMP activated protein kinase), 
ANT (nucleotide transporter), ERK (extracellular signal-activated kinases), G-6-P (glucose-6-
phosphate), GLUT1, GLUT4 (glucose transporters), HK (hexokinase), LDHA (lactate 
dehydrogenase A), MAE (malic enzyme), Myc (tumour suppressor, myelocytomatosis 
oncogene), p53 (tumour suppressor p53), HIF-1 (hypoxia-induced factor 1), PDH (pyruvate 
dehydrogenase), PDK (pyruvate dehydrogenase kinase), PFK (phosphofructokinase), PI3K 
(phosphatidylinositol-3-kinase), PPP (pentose phosphate pathway), ROS (reactive oxygen 
radicals), VDAC (voltage-mediated anion transporter). 
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1.2. Role oxidative phosphorylation in cancer metabolism  
Current advances in research of neoplastic diseases have improved our 
understanding of why metabolic reprogramming occurs in cancer cells. However, it 
is clear that one metabolic setting cannot be generalized to define the metabolism 
of all cells within the tumour. Therefore, functional mitochondria are indispensable 
for proliferation and survival of cancer cells (Jose, Bellance and Rossignol 2011).  
According to recent results emphasizing the relevance of mitochondria and OXPHOS 
in the tumour microenvironment, mitochondria are able to drive the metabolic 
turnover, act on the immune system, affect proliferative potential and cell survival 
as well as influence the processes of angiogenesis and metastases (Galluzzi et al. 
2010, Tan et al. 2015, Gentric, Mieulet and Mechta-Grigoriou 2017).  
 
1.2.1. Mitochondria and oxidative phosphorylation 
Mitochondria are double membrane organelles, that play a key role in a wide range 
of cellular processes from energy production and generation of reactive oxygen 
species, through regulation of biosynthetic pathways to cell death. There is a system 
of OXPHOS localized in the mitochondrial inner membrane (MIM), which is the 
principal feature of mitochondria. This system consists of an electron-transporting 
chain (ETC), which is composed of four complexes (CI-CIV) and linked the fifth 
complex - ATP synthase. In a multi-step process, within the four complexes of 
respiratory chain, electrons produced in the Krebs cycle utilize oxygen to water. 
During the gradual transfer of electrons to the final acceptor oxygen, an electrostatic 
and proton gradient is formed by means of the complexes (except from complex II) 
on the MIM. This gradient, also referred to as mitochondrial membrane potential 
(ΔΨm, i), is the driving force of ATP synthase that produces ATP from ADP and 
inorganic phosphate. To produce ATP, the OXPHOS system must be linked to 
adenosine nucleotide translocases (ANT1-3 in mammals) and a phosphate 
transporter, that mediate the transfer of ATP / ADP and phosphates across the MIM. 
The OXPHOS system is necessary for the production of ATP in non-proliferating 
post-mitotic somatic cells. Compared to proliferating cells having an active Krebs 
cycle, which is accompanied by efficient antioxidant defense to OXPHOS-derived 
ROS, non-proliferating cells have a higher level of respiration. 
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Proliferating cells, which include e.g. cells in the embryonic development as well as 
cancer cells, acquire a significant part of the necessary ATP from glycolysis, and 
therefore OXPHOS function is not as critical for them as for non-proliferating cells. 
 
1.2.2. DHODH pathway 
If nutrients such as aspartate or pyruvate become limiting, OXPHOS inhibition may 
also interfere with the anabolic pathways such as nucleotide synthesis. Pyrimidines 
are synthesized de novo from simple precursors in a six-step pathway, where the 
fourth and rate-limiting enzyme dihydroorotate dehydrogenase (DHODH) is 
localized in the MIM. De novo synthesis of pyrimidines is associated with respiration 
through the redox cycle of coenzyme Q. In this cycle, the oxidized form of coenzyme 
Q (CoQ) – ubiquinone is reduced to ubiquinol by electrons produced during 
conversion of dihydroorotate (DHO) to orotate by DHODH. Complex III then 
reoxidizes ubiquinol back to ubiquinone by transfer of electrons to cytochrome c. 
(Löffler et al. 2005). Functional respiration is therefore necessary for the activity of 
DHODH and pyrimidine synthesis.  
Deleterious mutations in mtDNA  lead to inhibition of tumour formation (Park et al. 
2009). Tumour cells with depleted mtDNA (rho0 cells) have non-functional OXPHOS 
as a result of lack of the mitochondria-encoded subunits and inability to assemble 
the functional respiratory complexes. It was proven that these cells are able to 
restore the mitochondrial functions by transferring whole mitochondria from the 
stroma when injected into mice (Bajzikova et al. 2019, Dong et al. 2017, Tan et al. 
2015). Bajzíková et. al show that DHODH-driven pyrimidine biosynthesis renewal 
after respiration recovery, rather than OXPHOS-mediated ATP production, is 
essential for initiation of tumorigenesis. Intriguingly, reactivation of CoQ redox-
cycling alone the using alternative oxidase (AOX) as an acceptor of electrons from 
reduced CoQ, is sufficient to drive DHODH and to allow cancer cells to form tumours 
(Bajzikova et al. 2019). The comparison of the linkage of de novo pyrimidines 
synthesis to ETC is shown in Figure 1.6.  
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FIGURE 1.6: Schematic representation of the linkage of de novo pyrimidines synthesis to 
ETC. Parental cells with mtDNA (A), derived mtDNA depleted rho0 cells (B), adapted from 
Bajzikova et al., 2019.  
 
1.3. Tumour microenvironment (TME) 
A tumour is a highly complex tissue with a wide variety of different cell types 
including supporting stromal cells, stem cells, immune cells and many others cell 
types, as is shown in Figure 1.7. The biology of tumours can no longer be understood 
simply by enumerating the traits of the cancer cells but must encompass the 
contributions of the “tumour microenvironment” for induction of tumorigenesis. 
(Hanahan and Weinberg 2011) 
 
1.3.1. Stromal cells in the tumour microenvironment 
Bone marrow-derived cells (BMDCs)  
Tumour-associated macrophages (TAMs) are a prototype of bone marrow-derived 
cells (BMDCs), whose presence in the tumour microenvironment was found in most 
experimental mouse models of tumours as well as in human tumours and are 
connected with a poor prognosis (Qian and Pollard 2010, Pollard 2004, Bingle, 
Brown and Lewis 2002). Their role is mostly tumour-promoting, showing the ability 
to modify the behaviour of tumour cells. The bidirectional interaction between TAM 
and TME forms a response to conditions in a specific region of the tumour, for 
example, by accumulating TAM in hypoxic or necrotic areas due to the release of 
hypoxia-induced chemoattractants (Murdoch, Giannoudis and Lewis 2004, White et 
al. 2004, Mantovani et al. 2006). TAMs subsequently contribute to angiogenesis (Lin 
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et al. 2006, Zumsteg and Christofori 2009). Moreover, TAMs play an important role 
in invasiveness and migration of cancer cells (Condeelis and Pollard 2006), since 
TAMs produce the epidermal growth factor (EGF), thereby increasing the 
invasiveness and migration of EGF receptor expressing EGFR (EGFR) cancer cells. 
On the other hand, cancer cells expressing CSF1 acting on TAM that express CSF1R. 
Together it induces a paracrine loop-driven co-migration and invasion of both cell 
types towards blood vessels. (Lin et al. 2001, Achkova and Maher 2016, Dwyer, 
Greenland and Pixley 2017).  
Adipocytes can participate in interactions with cancer cells in some types of 
tumours. For example in intra-abdominal tumours they support the growth of 
malignant cells through the transport of fatty acids, that promotes nutrient supply 
and actively help to recruit cancer cells through adipokine secretion (Vona-Davis 
and Gibson 2013, Nieman et al. 2011). 
There is evidence of various tumour-promoting functions of tumour associated 
neutrophils (TANs) in the tumour microenvironment including promotion of 
growth of the primary tumours and angiogenesis or increasing of ECM degradation 
and enhanced development of circulating tumour cells (Hurt et al. 2017, Nozawa, 
Chiu and Hanahan 2006, De Larco, Wuertz and Furcht 2004, Erler et al. 2009). On 
the other hand, tumour-suppressing effects were described after immunological or 
cytokine activation (Hicks et al. 2006, Colombo et al. 1992).  
Increased levels of inhibitory immune myeloid cell-derived suppressor cells 
(MDSCs) have been observed in various types of tumours in mice and humans. 
MDSCs are able to inhibit CD8+ T lymphocytes, induce Treg lymphocytes or 
contribute to the formation of the TAM phenotype, which suggests their tumour-
promoting potential (Sinha et al. 2007, Porta, Sica and Riboldi 2018). 
 
Tumour blood supply 
The angiogenic signals produced by cancer and TME cells during hypoxia activates 
angiogenesis and stimulates branching of the blood vessels to form a new vascular 
supply for the tumour. The most important angiogenic factor produced by cancer 
cells is vascular endothelial growth factor (VEGF), but in higher stages of tumours it 
can be replaced by other angiogenic factors i.e. platelet-derived endothelial cell 
growth factor (PD-ECGF), transforming growth factor (TGF)-β, angiogenin and 
others (Pang and Poon 2006) . Tumour vasculature is almost always heterogeneous 
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and disordered. Vascular leakage increases the interstitial fluid pressure and 
irregular blood flow resulting in increased oxygenation and nutrient distribution in 
TME (Carmeliet and Jain 2011, Mittal, Ebos and Rini 2014). 
Pericytes provide structural support to endothelial cells in blood vessels. Tumours 
with low occurrence of pericytes show a poor prognosis associated with higher 
tumour cell invasiveness and metastasis. Tumour vasculature coverage could 
therefore act as a key negative regulator of metastasis (Balkwill, Capasso and 
Hagemann 2012, Cooke et al. 2012). 
 
Cancer associated fibroblasts (CAFs)   
Cancer associated fibroblasts (CAFs) may originate from multiple precursors i.e. 
smooth muscle cells, endothelial cells or MSCs. They produce a number of growth 
factors that are mitogenic for tumour cells, induce the epithelial-mesenchymal 
transition (EMT) and contribute to the immunosuppressive microenvironment by 
producing chemoattractants recruiting other types of stromal cells to the TME. 
Fibroblasts also contribute to the TME composition by their secretion of ECM 
components and ECM re-modelling enzymes (Balkwill et al. 2012, Erez et al. 2010, 
Farhood, Najafi and Mortezaee 2019). 
  
Cells of the immune system    
Tumour-associated B lymphocytes are found primarily at the periphery of  invasive 
tumours  and lymph nodes adjacent to tumours (Sarvaria, Madrigal and Saudemont 
2017). Regulatory B lymphocytes (Breg) have been found to have tumour-promoting 
impact in some cancer types e.g. ovarian cancer, non-small lung carcinoma and 
cervical cancer (Schioppa et al. 2011, Olkhanud et al. 2011, Sarvaria et al. 2017). 
Some studies point to poor prognosis after the inhibition of cytotoxic T lymphocytes 
by B cells (Qin et al. 1998).  However, in some types of breast (Coronella et al. 2001) 
or ovarian carcinomas (Milne et al. 2009) B cells infiltration into the tumour 
microenvironment is associated with a good prognosis 
Infiltration with CD4+ T lymphocytes, e.g. helper TH2 lymphocytes, recruit B cells 
and TH17 cells into the tumour and activate their secretion of pro-inflammatory 
cytokines, which could enhance chronic inflammation and tumorigenesis (Fridman 
et al. 2012, Becht et al. 2016, Balkwill et al. 2012, Anderson, Stromnes and 
Greenberg 2017). Beside TH2 cells, high level of regulatory T lymphocytes (Treg) in 
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the tumour microenvironment is associated with worse prognosis in many cancer 
types i.e. breast (Bates et al. 2006), ovarian (Curiel et al. 2004) or pancreatic cancer 
(Hiraoka et al. 2006). 
 
FIGURE 1.7: Components of tumour microenvironment. The cancer cells are in primary 
tumours surrounded by complex tumour microenvironment within bone-marrow derived cells 
as tumour associated macrophages (TAMs) or mesenchymal stem cells, endothelial cells and 
tumour associated fibroblasts (CAFs). Adapted from Joyce and Pollard, 2009.   
 
1.3.2. Mesenchymal stem cells (MSCs) 
Although MSCs belong to the group of bone marrow-derived cells, they have unique 
role in mitochondrial transfer into cancer cells. As was written above, these 
adherent multipotent cells can be found mainly in the bone marrow although their 
origin is not hematopoietic. MSCs are able to differentiate into various cell types of 
mesenchymal cells i.e. along the osteogenic, adipogenic and chondrogenic lineages, 
which is very important for tissue damage reparations. Thanks to self-renewal 
potential, MSCs keep their multipotency also after cell division. MSCs can be isolated 
from the bone marrow but are present also in other tissues such as skeletal muscle, 
umbilical cord, amniotic fluid, foetal liver and adipose tissue (Guan and Chen 2013, 
Jin et al. 2013). MSCs are frequently found in stromal niches of various tumours 
(Nwabo Kamdje et al. 2017).  
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Due to their ability to repair tissues and protect transformed cells from 
chemotherapy MSCs play an important role in the tumour microenvironment in all 
stages of tumour development including metastatic expansion. Through the 
secretion of various cytokines and growth factors such as CCL5, TGF-β, IL-6, IL-10, 
VEGF, MMP, SDF-1 or Neuregulin1, the MSCs are able to modulate immune reaction 
and facilitate neovascularization processes and angiogenesis, which are the key 
aspects for subsequent tumour growth and invasiveness (Zhang et al. 2013a, Han et 
al. 2014, Donnelly et al. 2014, Kucerova et al. 2014, Nwabo Kamdje et al. 2011). 
There are several pieces of evidence that MSCs are able to differentiate into CAFs 
both in vitro after long-term cultivation in tumour cell-conditioned medium via a 
TGFβ1/Smad3-dependent mechanism (Yu et al. 2014, Mishra et al. 2008, Sugihara 
et al. 2015) and in vivo, where the MSCs derived CAFs promote metastases in 
advanced solid tumours (Margolin et al. 2015, Hong et al. 2015, Mühlethaler-Mottet 
et al. 2015, Liao et al. 2015).   
MSCs are able to trans-differentiate. Trans-differentiation is the process of cell 
fusion of both cancer cells and other components of the tumour microenvironment, 
which results in tissue remodelling and tumour stroma formation. Trans-
differentiation of MSCs has been reported, for example, in human melanoma 
(Kucerova et al. 2014), breast or ovarian carcinoma (Yang, Otte and Hass 2015), 
lung carcinoma (Wei et al. 2014) and others. Positive and negative effect of TME by 
MSCs is shown in Figure 1.8.  
 
Figure 1.8: Positive and negative effects of MSCs in TME.  
MSCs have a number of tumour-promoting functions through which they modulate tumour 
cells or cells of the tumour microenvironment. Various factors produced by MSCs, which 
positively affect tumour growth are depicted in green. On the other hand, also tumour-
suppressive effects of MSCs were described. Adapted from Barcellos-de-Souza et al., 2013.  
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However, several studies describe anti-neoplastic properties of MSCs in e.g. Kaposi's 
sarcoma or non-Hodgkin's lymphomas (Khakoo et al. 2006, Secchiero et al. 2010) as 
well as induction of apoptosis in endothelial cells  of newly formed vessels 
(Secchiero et al. 2010, Otsu et al. 2009). In vivo experiments using co-injection of 
glioma cells and MSCs caused reduce tumour volume and its vascularization (Ho et 
al. 2013). Wang et al. showed, that MSCs inhibit tumour growth in vivo and 
proliferation and migration of lung adenocarcinoma in vitro through oncostatin-M 
secretion (Wang et al. 2012, Barcellos-de-Souza et al. 2013).  
Similarly, as for immune cells, tumour-promoting or tumour-suppressing role of 
MSCs depends on TME, which modulates the function of MSCs means of properties 
such as cell type composition, hypoxia, pH or inflammation. 
 
1.4. Intercellular communication  
Intercellular communication usually introduces one of the classic ways in which the 
transmission of information between cells is mediated. Communication with the 
environment, besides proper nutrient intake, is one of the indispensable conditions 
for cell survival (Vander Heiden et al. 2009). Traditional ways of intercellular 
communication include direct interactions by cell-to-cell contact, interactions of 
receptors with soluble ligands, vesicle transfer, or transmission through gap 
junctions. Cancer cells are able to activate their surrounding microenvironment by 
secreting cytokines, growth factors and proteases, which can act in cascades of 
autocrine and paracrine signalling, indicated in Figure 1.9. This signalling disrupts 
homeostasis of healthy surrounding tissue and induces angiogenesis and 
inflammation. Angiogenesis is necessary for both, the growth of the tumour and for 
progression of tumour from pre-malignant into malignant stage. At the same time, 
the cancer cells can initiate secretion of ECM components supporting migration an 
invasiveness of cancer cells and reduce the expression of protease inhibitors a well 
as upregulate expression of serine proteases and matrix metalloproteases that 
degrade and rebuild the ECM. All these components, together with the tumour-
derived growth factors, affect fibroblasts in the tumour microenvironment and 
activate them. (Mueller and Fusenig 2004, Brücher and Jamall 2014). 
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Figure 1.9: Crosstalk between cancer cells and tumour microenvironment. Cancer cells 
are able to activate the surrounding stromal environment in autocrine and paracrine manners 
by secreting growth factors and proteases. This signalling results in cancer cells migration, 
angiogenesis and activation of the cells of immune system and cancer associated fibroblasts. 
Adapted from Mueller and Fusenig, 2004.   
 
A special type of communication of cells is the exchange of whole organelles. This 
type of communication corresponds to adaptation to external stress and improves 
the ability of tumour cells to survive.  
Intercellular transfer of organelles has been described in many different cell types 
of both human and rodents origin, differentiated and multipotent cells, malignant 
and benign tumours and can be realized by different mechanisms including cellular 
fusion, transport of microvesicles, formation of exosomes and apoptotic bodies, 
transfer via gap junctions or through tunnelling nanotubes (TNTs) as shown in 
Figure 1.10 (Torralba, Baixauli and Sánchez-Madrid 2016). In all cases, transfer of 
organelles includes their active transport via the cytoskeletal system in the cell, 
which is of high ATP demand. (Spees et al. 2006, Gurke et al. 2008).  
Beside strictly unidirectional transfer from one cell type to the other (Koyanagi et 
al. 2005), bidirectional transfer between the two type of cells has been reported, too 
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(He et al. 2011, Yasuda et al. 2011). The model of primary human proximal tubular 
epithelial cells (RPTEC) shows bidirectional transfer not only for organelles but also 
for many cargo vesicles (Domhan et al. 2011) as well as for small ions as calcium, 
this was observed in human retinal pigment epithelial (RPE) cells, human 
neuroblastoma SH-SY5Y cells  and human embryonic kidney HEK 293 cells (Smith, 
Shuai and Parker 2011, Wittig et al. 2012). 
 
Figure 1.10: Cellular mechanisms of intercellular mitochondrial transfer. 
Mitochondria can be transferred by various mechanisms. First of them is the exchange of 
various extracellular vesicles such as exosomes, various microvesicles and apoptotic bodies or 
multivesicular body (MVB). These extracellular vesicles contain whole mitochondria or their 
fragments – depicted in yellow and orange (Torralba et al. 2016, Phinney et al. 2015) (A). 
Another way of the transfer is cellular fusion, when two independent cells fuse their plasmatic 
membranes and share their content including organelles and other cytosolic compounds, while 
the nuclei remain intact after the fusion (Oh et al. 2003) (B). In alveolar cells the mitochondrial 
transfer from BMSCs was detected after LPS treatment. The treatment increased connexin 43 
expression in alveolar cells, that facilitates the attachment of BMSCs and formation of gap 
junctional channels, microvesicles and tunnelling nanotubes for mitochondrial transfer (Islam 
et al. 2012, Torralba et al. 2016)(C). Figure adapted from Torralba et al., 2016. 
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1.5. Mitochondrial transfer in vitro between mammalian cells 
Transfer of mitochondria between cells results in their incorporation into the 
endogenous mitochondrial network in the recipient cells, which can influent cellular 
metabolism. This has significant implication for the pathology of mitochondria 
leading to enhancement of neoplastic diseases as a result of reprograming of 
signalling and metabolic pathways (Torralba et al. 2016). 
 
1.5.1. Intercellular transfer from MSCs to tumour cell lines 
Progenitor stem cells, present in almost every tissue, have the propensity to repair 
possible tissue damage or to replace depleted cells. These cells can be also 
supported by MSCs. The stem cells differentiate in the region of damage to replace 
the injured cells and produce various growth factors to communicate with their 
neighbourhood. Due to these characteristics are MSCs often used for in vitro studies 
investigating mitochondrial transfer to cells with mitochondrial dysfunctions 
(Prockop, Gregory and Spees 2003). 
The first evidence of mitochondrial transfer was documented by Spees et al. 
between MSCs and fibroblasts which were cultivated with adenocarcinomic human 
alveolar basal epithelial cells with depleted mtDNA (A549 rho0). The A549 rho0 
cells were prepared by long-term cultivation with low concentration of ethidium 
bromide (EtBr). Upon co-cultivation with MSCs or fibroblasts, A549 rho0 cells 
acquired functional mitochondria and restored aerobic respiration (Spees et al. 
2006). Other studies subsequently described mitochondrial transfer between MSCs 
and various types of breast cancer cells (MCF-7, MDA-MB) or ovarian cancer cells 
(OVCAR-3, SKOV-3). Except the transfer between two different cell types – 
heterocellular transfer, also homocellular transfer between cells of one type was 
observed (Pasquier et al. 2013, Caicedo et al. 2015). The study on rho0 variant of 
human osteosarcoma cell line (143B) rho0 cells showed, that the extent of 
mitochondrial disruption the potential recipient cells is very, such that there was no 
mitochondrial transfer from MSCs to rho0 cells after partial damage of mitochondria 
(Cho et al. 2012). In another study, Wharton's jelly-derived MSCs, a stem cells 
isolated from postpartum umbilical cord, were used for co-culture studies with 
143B rho0 cells. The results showed that rho0 cells, which received functional 
mtDNA, recovered the ability to respire and to restore their normal cellular 
behaviour (Lin et al. 2015).  
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1.5.2. Intercellular transfer between tumour cells  
As mentioned above, the transfer of mitochondria exists not only between healthy 
and cancer cells but cancer cells can also transfer mitochondria to each other 
(Pasquier et al. 2013).  The mitochondrial transfer was observed between various 
mesothelioma cell lines (MSTO-211H, VAMT, H-Meso) as well as between non-
malignant mesothelial LP9 and Met5A cells, but interestingly there was no evidence 
of transfer when mesothelial and mesothelioma cells were co-cultured (Lou et al. 
2012). Another piece of evidence of transfer via TNTs is from the study with human 
lung squamous cell carcinoma cells (LSCC), where the TNTs were observed not only 
as a phenomenon of in vitro cell culture but also and more importantly in tissue 
sections (Antanavičiūtė et al. 2014). Using an in vitro bladder cancer cell co-culture 
model, Lu et al. demonstrated heterocellular mitochondrial transfer between two 
cancer cell lines. Formation of TNT and uni-directional transfer of mitochondria 
occurred between highly invasive T24 cells and less invasive RT4 cells. This 
spontaneous intercellular mitochondria trafficking between the cell types was 
followed by increased Akt activation, mTOR signalling, and invasiveness of RT4-
Mito-T24 cancer cells, that originated by transferring of mitochondria from T24 to 
R24 cells (Lu et al. 2017). Another model for mitochondrial transfer represents 
PC12 cell line derived from a pheochromocytoma of the rat adrenal medulla. There 
is evidence of the transfer between un-treated PC12 and UV-treated PC12 cells in 
the co-culture, where UV-treated PC12 cells received healthy mitochondria from 
their un-treated counterparts.  (Wang and Gerdes 2015b, Bukoreshtliev et al. 2009, 
Rustom et al. 2004). 
 
1.5.3. Intercellular transfer between non-cancerous cells 
There are examples of intercellular mitochondrial transfer between non-cancerous 
cells. In addition to neoplastic diseases, heart disorders such heart attack and 
ischemia are the most common cause of death in developed countries. Therefore, 
intercellular transfer of mitochondria seems to be a possible way of the therapeutic 
modality in this context. The donation of functional mitochondria from MSCs to 
cardiomyocytes with dysfunctional or damaged mitochondria leads to the 
restoration of mitochondrial function and improves the condition of the affected 
cells (Plotnikov et al. 2008, He et al. 2011, Acquistapace et al. 2011, Oh et al. 2003).  
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Liu et al. simulated ischemic reperfusion in human umbilical vein endothelial cells 
(HUVEC) by cultivation of cells under the reduced oxygen supply. Subsequent co-
cultivation with MSCs with both functional and damaged mitochondria revealed, 
that unlike damaged MSCs, co-cultivation with healthy MSCs restored mitochondrial 
function in HUVEC cells indicating the regenerative potential of mitochondrial 
transfer (Liu et al. 2014).  
Rats exposed to cigarette smoke as well as human bronchial epithelial cells (BEAS-
2B) are in vivo and in vitro models of chronic obstructive pulmonary disease (COPD), 
a disease expressing mitochondrial disfunction. Co-cultivation of BEAS-2B with 
human-induced pluripotent stem cell-derived MSCs (iPSC-MSCs) or grafting of adult 
bone marrow MSCs (BM-MSCs) into rat, respectively, result in renewal of damaged 
mitochondria in recipient cells and attenuate lung damage caused by cigarette 
smoke (Li et al. 2014). 
Similarly, mitochondrial transfer between primary human RPTEC and human 
mammary epithelial cells (HMEC)  (Domhan et al. 2011) or MSCs and rat renal 
tubular cells (Plotnikov et al. 2010) was detected.  
 
1.6. Mitochondrial transfer between mammalian cells in vivo 
Occurrence of intercellular mitochondrial trafficking in vivo is rare. Anyway, there 
are several studies showing mitochondrial trafficking under pathophysiological 
conditions.  
Phylogenetic and sequencing studies on the canine transmissible venereal tumour 
(CTVT) demonstrate that cumulative damage of mitochondrial DNA lead to periodic 
transfer of mitochondria from host animals into the cancer cells (Strakova et al. 
2016, Rebbeck, Leroi and Burt 2011). Islam et al. reported mitochondrial transfer in 
a mouse model of acute lung injury. The mice were exposed to endotoxin - 
lipopolysaccharide (LPS) and subsequently grafted with mouse or human bone 
marrow-derived MSCs. After alveolar attachment, BMSCs transferred their 
mitochondria to the alveolar epithelium. Connexin 43 (Cx43), expressed on all 
structures including microvesicles, nanotubes and gap junctional channels, was 
found as a crucial factor affecting the alveolar attachment of BMSCs, which helps to 
transport functional mitochondria into the alveolar cells, as presented in Figure 1.10 
– C  (Islam et al. 2012, Sinha et al. 2016). 
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1.7. Tunnelling nanotubes (TNTs)  
Many publications describe mitochondrial transfer via TNTs as the major 
mechanism by which this organelle exchange takes place (Pasquier et al. 2013, Lou 
et al. 2012, Antanavičiūtė et al. 2014, Wang and Gerdes 2015a, Koyanagi et al. 2005, 
Domhan et al. 2011, He et al. 2011, Liu et al. 2014, Islam et al. 2012).  Moreover, 
TNTs can transport various vesicles as early endosomes, endoplasmic reticulum 
(ER), Golgi apparatus (GA) or lysosomes (Smith et al. 2011, Wang et al. 2011, 
Osswald et al. 2015, Rustom et al. 2004) as well as ions (Ca2+) or small molecules as 
miRNAs. Furthermore, TNTs transfer pathogens like bacteria, viruses and prions, 
that results in spreading of the pathologies (Onfelt et al. 2006, Hashimoto et al. 2016, 
Kumar et al. 2017, Gousset et al. 2009, Panasiuk et al. 2018, Jansens et al. 2017).   
 
1.7.1. TNTs formation  
There are two possible mechanisms of TNT formation (ref.). Both models require 
active cell motion and cytoskeleton remodelling. The first model – referred to as 'cell 
dislodgement' mechanism involves a membrane fusion between donor and 
recipient cells, that are in close contact. Their subsequent migration in opposite 
directions then prolong TNT between each other. The second model, known as the 
actin-driven mechanism, consist of extension of filopodia-like protrusion from one 
cell to distant cell, where the membrane fusion at the contact site gives rise to the 
TNT structure (Abounit, Delage and Zurzolo 2015, Ariazi et al. 2017, Hekmatshoar 
et al. 2018). As mentioned above, several studies report the key role of Cx43 in TNT 
production and attachment and subsequent mitochondrial transmission (Berridge 
et al. 2016, Osswald et al. 2015) 
 
1.7.2. Role of cytoskeleton in TNTs formation 
TNTs are thin transient plasma membrane extensions forming during the 
interphase of the cell cycle. They are very heterogeneous structures in terms of the 
length, width, longevity, the way of formation and the composition of the 
cytoskeletal components i.e. actin filaments, microtubules (MTs) and intermediate 
filaments (IFs). The content of cytoskeletal components varies depending on the 
properties of TNTs and the character of the cells involved in this intercellular 
linkage. The organization and position of all three cytoskeletal elements are 
expected to play crucial role in the effective transport of material via TNTs and in 
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the stability of TNTs (Ariazi et al. 2017, Resnik et al. 2018). These structures can 
span various lengths i.e. up to several hundreds of micrometres and diameter ranges 
from 50 to 1500 nm (Vignais et al. 2017, Hekmatshoar et al. 2018).  
Interplay between IFs in donor and recipient cells is documented to have a key role 
in formation of TNTs connecting RT4 and T24 urothelial cell, squamous carcinoma 
cells and mesothelioma H2052, VAMT, and MSTO-211H cells (Sáenz-de-Santa-María 
et al. 2017, Veranic et al. 2008, Ady et al. 2014), while evidence about MT-IF 
interplay in TNTs is missing (Resnik et al. 2018). It is indisputable that actin 
filaments are essential for the formation and propagation of all TNTs, while MTs are 
present preferentially in TNTs of larger diameter and contribute to their stability 
and longevity (Osteikoetxea-Molnár et al. 2016, Jansens et al. 2017, Panasiuk et al. 
2018, D'Aloia et al. 2018).  
Present work assumes that there are actin filaments and MTs inside the TNTs and 
that both of these cytoskeletal elements are important as highways for motor 
proteins, which transport their cargos between the two connected cells.  
  
Figure 1.11: Schematic representation of mitochondrial transfer via the intercellular 
TNT link. Moving through tunnelling nanotubes appears to be a relevant way of transferring 
mitochondria with mtDNA into a cell with disrupted mtDNA. This process is driven by protein 
motors kinesin-1 and dynein, which carry cargo in the anterograde and retrograde directions. 
For one-way intercellular movement of mitochondria by TNTs, kinesin appears to be more 
appropriate. The mitochondrial load is attached via adapter proteins Miro1 (or Miro2) and 
miltons (Trak1 and Trak2 in humans) (Lovas and Wang 2013, Torralba et al. 2016, Ahmad et 
al. 2014). Adapted from Torralba et al., 2016. 
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1.7.3. Miro1 protein as a regulator of intercellular mitochondrial transfer 
From all cytoskeletal compartments, transfer on MTs is the most well described. The 
process of transferring mitochondria through TNT is driven by the motor protein 
kinesin-1. It has been shown that kinesin-1 shifts the cargo along the fibre in the 
anterograde direction, from minus to plus end of the microtubule. In the opposite, 
retrograde direction, dynein probably acts as a molecular motor. The mitochondria 
are then attached to the kinesin via the adapter proteins Miro1, see Figure 1.11 
(MacAskill and Kittler 2010, Guo et al. 2005, Glater et al. 2006, Fransson, Ruusala 
and Aspenström 2006).  
Primary structure of Miro proteins, shown in Figure 1.12, contains two GTPase 
domains as well as two helix-loop-helix structural EF domains, which protrude into 
the cytosol and are responsible for Ca2+ binding.  Except these domains, Miro protein 
has a carboxy-terminal transmembrane domain, which anchor the outer 
mitochondrial membrane (OMM) (Peters et al. 2018).  
Figure 1.12: Primary structure of Miro proteins. Figure adapted from Stephen et al. 2015.   
 
Miro1 is an essential protein in mitochondrial transport in both in vitro and in vivo 
models. Co-cultivation of epithelial cells with MSCs show increased mitochondrial 
transfer in MSCs with Miro1 overexpression in contrast to decreased efficacy of 
mitochondria transfer in co-culture with Miro1 knockdown MSCs. In mouse model 
of allergic airway inflammation with inhibited complex I respiratory chain using 
rotenone, grafting of MSCs with overexpressed Miro1 has been associated with 
higher therapeutic efficacy (Ahmad et al. 2014). 
Another study confirmed the key role of Miro1 in mitochondrial transfer using in 
vitro model of ischemia in astrocytes and in PC12 cells with mitochondria damaged 
by EtBr. Increased mitochondrial transfer through TNTs was occurred in both 
models showed increased frequency of mitochondrial transfer and subsequent 
restoration of neuronal function after intravenous injection of MSCs overexpressing 
Miro1 (Babenko et al. 2018).   
26 
 
1.7.4. The mechanism of mitochondrial transport  
As mentioned above, the transport of mitochondria along microtubules is mediated 
by the engine proteins kinesin and dynein, which transfer mitochondria through 
many adapter proteins. In a study on Drosophila, dMiro was found to interact 
directly with Milton protein and form a protein complex that regulates 
mitochondrial transport (Guo et al. 2005).  
Later, mammalian orthologs of the Milton protein, called TRAK 1 and TRAK2 (or also 
OIP106 and OIP98/Grif-1), which are able to form complexes with two mammalian 
orthologs of dMiro (Miro1 and Miro2), have also been identified (Brickley et al. 
2005). Unlike drosophila, TRAK1 and TRAK2 do not appear to be specific factors for 
mitochondria transmission in the cells, although they participate in regulation of 
transfer of other cargos as endosomes (Webber, Li and Chin 2008, Kirk, Chin and Li 
2006). 
It was shown that mitochondrial transfer is dependent on the cytosolic levels of 
calcium in both neuronal and non-neuronal cells. It was shown, that resting 
physiological concentration of Ca2+ (50-100 nM) is responsible for maximal 
mitochondrial motility, whereas total suppression of the mitochondrial activity 
occurs in 1 μM Ca2+ concentration (Yi, Weaver and Hajnóczky 2004). The EF 
domains of Miro protein are calcium sensors, that are able to mediate calcium-
dependent inhibition of mitochondrial transfer (Macaskill et al. 2009, Wang and 
Schwarz 2009, Saotome et al. 2008).  
 
Figure 1.13: Two models of the mechanism of mitochondrial stopping. Figure adapted 
from MacAskill and Kittler, 2010.   
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Two models of the mechanism of this inhibition were described, as is shown in 
Figure 1.13. The first model shows disruption of Miro1 and kinesin interaction after 
calcium binding. This results in detachment of mitochondrion from the transport 
machinery and leads to motors inactivation (Macaskill et al. 2009). The second 
model observed in Drosophila presumes, that high level of calcium blocks kinesin 
connection to microtubules and binds it directly to dMiro protein linked to 
mitochondria, which results to uncoupling mitochondria from the microtubule 
transport pathway (Wang and Schwarz 2009, MacAskill and Kittler 2010). However, 
the exact mechanism of mitochondria movement regulation remains unclear. 
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2. Aims 
QUESTION 1 
Is there a link between OXPHOS and initiation of tumorigenesis? 
 
AIM 1.1 
To investigate the tumour formation ability of mtDNA deficient murine metastatic 
melanoma (B16) and murine metastatic breast carcinoma (4T1) cells.  
 
AIM 1.2 
To examine metabolic state of B16 a 4T1 sub-lines with different mtDNA levels.  
 
AIM 1.3 
To characterize the influence of mitochondrial transfer in B16 and 4T1 sub-lines.  
 
 
QUESTION 2 
Is mtDNA transfer in B16 and 4T1 cells realized via the transport of intact 
mitochondria mediated by TNTs? 
 
AIM 2.1 
To verify the transfer of intact mitochondria in vivo. 
 
AIM 2.2 
To investigate intercellular transfer of mitochondria via TNTs.  
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3. Material 
3.1. Chemicals 
Chemical Supplier Catalog number 
Cell culture 
Dimethylsulfoxide (DMSO) Sigma D2650 
Ethidium bromide (EtBr)  Sigma E1510 
Ethylenediaminetetraacetic acid (EDTA)  Sigma E7889 
FluoroBrite™ DMEM Medium TermoFisher A1896702 
Isopropanol  Penta 17500 
Poly-L-lysine solution Sigma P4707 
Trypsin/EDTA (0,25 % w/v) Sigma T4049 
 
3.2. Media  
 
Chemical Supplier Catalog number 
Complete growth RPMI medium for 4T1 sub-lines culturing 
D(+)-Glucose Roth HN06.3 
FBS (10 % w/v) Sigma F7524 
Penicilin G (sodium salt) (100 U/ml) Sigma P3032 
RPMI-1640 Medium Sigma R8758 
Sodium pyruvate (1 mg/ml) Sigma P8574 
Streptomycin (sulfate) (100 μg/ml) Sigma S9137 
Uridin (0,05 mg/ml) Sigma U3750 
Complete growth DMEM medium for B16 sub-lines culturing 
D(+)-Glucose Roth HN06.3 
DMEM (Dulbecco’s modified Eagle medium) Sigma D6429 
FBS (10 % w/v) Sigma F7524 
Penicilin G (sodium salt) (100 U/ml) Sigma P3032 
Sodium pyruvate (1 mg/ml) Sigma P8574 
Streptomycin (sulfate) (100 μg/ml) Sigma S9137 
Uridin (0,05 mg/ml) Sigma U3750 
Complete growth MesenCult medium for MSCs culturing 
MesenCult™ basal medium (Mouse)  StemCell technologies 05514 
MesenCult™ 10X supplement (Mouse) StemCell technologies 05515 
MesenPure™ StemCell technologies 05500 
Penicilin G (sodium salt) (100 U/ml) Sigma P3032 
Streptomycin (sulfate) (100 μg/ml) Sigma S9137 
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3.3. Antibodies and mounting media 
Chemical Supplier Catalog number 
Primary antibodies 
Anti-Alpha-tubulin  abcam ab190573  
Anti-DNA mouse monoclonal Progen 61014  
Anti-Ki67  abcam ab15580 
Anti-TFAM rabbit polyclonal abcam ab131607  
Anti-TOM20  Santa Cruz Biotechnology sc11415 
Secondary antibodies 
Abberior STAR 580  Abberior Instruments  ST580 
Abberior STAR RED  Abberior Instruments  STRED 
Alexa Fluor 488 goat anti-rabbit IgG  Life Technologies  A21245 
Alexa Fluor 555 goat anti-mouse IgM  Life Technologies  A21236 
Hoechst 33342  Sigma 14533 
Mounting media 
Aberrior mount liquid  Abberior Instruments MM-2009-2X15ML 
VECTASHIELD® antifade mounting medium 
with DAPI  Vector laboratories  H-1200 
VECTASHIELD® antifade mounting medium  Vector laboratories  H-1000 
 
3.4. Immunofluorescent dyes 
Chemical Supplier Catalog number 
MitoTracker™ Orange CM-H2TMRos  ThermoFisher M7511 
MitoTracker™ Deep Red FM  ThermoFisher M22426 
SiR-tubulin kit SpiroChrome CHF420.00 
 
 
3.5. Kits 
Chemical Supplier Catalog number 
Photolitography 
SYLGARD® 184 silicone elastomer kit Sigma 761036 
Cell Viability Assay 
CellTiter-Glo® luminescent cell viability assay Promega G7570 
Total gDNA isolation 
Wizard® genomic DNA purification kit Promega  A1120 
Total protein concentration measurement 
Pierce™ BCA protein assay kit ThermoFisher 23225 
NAD/NADH Assay 
NAD/NADH-Glo™ assay Promega G9071 
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3.6. Buffers  
Chemical Supplier Catalog number 
Isolation buffer for MSCs 
FBS (10 % w/v) Sigma F7524 
Penicilin G (sodium salt) (100 U/ml) Sigma P3032 
Streptomycin (sulfate) (100 μg/ml) Sigma S9137 
PBS 1x     
Wash buffer for immunofluorescence staining  
Glycine Serva 23390.30 
TRITON™ X-100 Sigma T8787 
TWEEN® 20 Sigma P7949 
PBS 1x     
Citrate buffer for antigen restoration (10mM, pH 6)  
Citric acid 0,1M Sigma  251275 
Sodium citrate 0,1M  Sigma  1613859 
Water     
RIPA (Radio-immunoprecipitation assay) lysis buffer 
EDTA 1mM Sigma E7889 
NP-40 1% Sigma 74385 
SDS 0,1% Sigma 436143 
Sodium deoxycholate 0,5% (w/v) Sigma D6750 
Sodium chloride 150mM Serva 39781.02 
Tris 50mM (pH 8) Serva  37190.03 
 
3.7. Primers  
Name 
Sequence 5´-XXX-3´ 
Forward Reverse 
mMito1  CTAGAAACCCCGAAACCAAA CCAGCTATCACCAAGCTCGT 
B2M1  GCTGGGTAGCTCTAAACAATGTATTCA CCATGTACTAACAAATGTCTAAAATGGT 
 
3.8. Enzymes  
Chemical Supplier Catalog number 
DNase I Roche 11284932001 
Collagenase Sigma C7657 
 
3.9. Experimental models  
3.9.1. Cell lines  
Cell line Supplier Identifier 
4T1 ATCC CRL-2539 
B16 ATCC CRL-6323 
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MSCs 
Murine MSCs are multipotent stromal cells that are able to differentiate into a 
variety of cell types (osteoblasts, chondrocytes, myocytes and adipocytes). All cells 
were isolated from BALB/c su9DsRed2 or C57BL/6J su9DsRed2 mice.  
 
4T1 sub-lines  
 4T1 is 6-thioguanine-resistant adherent murine cell line of an animal stage IV 
human breast cancer syngeneic with BALB/c mouse strain.  
Cell sub-line Phenotype 
4T1  parental cells with standard mtDNA content 
4T1 rho0 cells with depleted mtDNA 
4T1 rho0 D5-D60 cells with various mtDNA content derived from tumours 
4T1 rho0 GFP (LV)  GFP is expressed diffuse in cytoplasm 
4T1 rho0 pmGFP/nBFP GFP is expressed in plasmatic membrane and BFP in nucleus 
 
B16 sub-lines  
B16 is adherent murine cell line of melanoma syngeneic with C57BL/6J mouse 
strain.  
Cell sub-line Phenotype 
B16  parental cells with standard mtDNA content 
B16 rho0 cells with depleted mtDNA 
B16 rho0 nBFP BFP is expressed in nucleus 
B16 rho0 DP 
BFP is expressed in nucleus and transfered mitochondria 
espress dsRed protein 
 
3.9.2. Mice 
Animal studies were performed according to the guidelines of the Czech Animal 
Ethics Committee and were approved by the respective local Animal Ethics 
Committee.  
Transgenic mice expressing red fluorescent protein in somatic cell mitochondria 
(the CAG/su9-DsRed2 transgene) were generated in the Transgenic Unit of the 
Czech Centre for Phenogenomics, Institute of Molecular Genetics, Prague, Czech 
Republic, using a pronuclear injection from the construct provided by prof. Masaru 
Okabe (Osaka University, Japan) (Hasuwa et al. 2010) and C57BL/6N mice (Dong et 
al. 2017). 
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C57BL/6J mice were used as syngeneic host animals for grafting B16 sub-lines  
C57BL/6Nsu9DsRed2 mice were used for isolation of MSCs for co-cultures with B16 sub-
lines 
Balb/c mice were used as syngeneic host animals for grafting 4T1 sub-lines  
Balb/csu9DsRed2 mice were used for isolation of MSCs for co-cultures with 4T1 sub-lines 
 
3.10. Instruments  
Instrument Supplier 
Cell culture 
Centrifuge 5415R Eppendorf 
Centrifuge 5804R Eppendorf 
Centrifuge MiniSpin Plus Eppendorf 
Flow box SafeFAST Classic 218 A Schoeller 
Incubator Sanyo CO2 Schoeller 
Water bath TW20 Julabo GmbH 
Microscopes  
Abberior STED 775 QUAD scanning microscope Abberior Instruments 
Confocal inverted microscope Leica SP8 SMD – FLIM Leica Microsystems 
Leica DMIL LED microscope Leica Microsystems 
Confocal microscope Leica TCS SP5 AOBS Tandem Leica Microsystems 
Nikon Eclipse E400 Nikon 
Other instruments 
Analytical scales Mettler Toledo 
Flowcytometer BD FACS Aria™ Fusion BD Biosciences 
HistoCore MULTICUT – Semi-automated rotary microtome Leica Biosystems 
Innovatis CASY® cell counter Innovatis 
Real Time PCR System Eco™ Illumnia Illumnia 
Tecan Infinitive M200 Tecan 
Ultrasound Vevo 770 VisualSonics 
Softwears 
Amira 6  Fei Systems 
Huygens professional version software 18.10  Scientific Volume Imaging  
ImageJ Fiji 
LAS v4.5 software Leica Microsystems 
Photoshop Adobe Photoshop Adobe 
Prism GraphPad 
  
Strain Supplier Identifier 
C57BL/6 mice Jackson Laboratories  C57BL/6  
Balb/c mice  Jackson Laboratories  Balb/c 
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4. Methods 
4.1. Cell culture  
All manipulations with the cells were performed in the sterile atmosphere of 
laminar flow box and all used equipment was sterile, autoclaved or disposable.  
All cell lines were grown in the incubator at 37°C under 5% CO2 atmosphere and 
95% humidity. Cells were split according to their growth rate, usually when reached 
80 - 90% confluence. 
 
4.1.1. Cell freezing and thawing  
The cells were frozen in cryovials in 10% DMSO in the standard medium and stored 
in liquid nitrogen. For thawing, the cells were removed from liquid nitrogen and 
immediately placed in the cryovials into a water bath of 37 °C. After thawing, the 
content of the cryovial was diluted in pre-warmed medium and centrifuged at 300x 
g for 5 min at room temperature. The supernatant was removed, and cells were 
resuspended in fresh culture medium. 
 
4.1.2. Cell passage and counting 
The medium was aspirated from the culture flasks, the cells were washed twice with 
PBS and then incubated for approximately 5 min with an appropriate volume of 
trypsin solution in PBS (0.25% w/v) in an incubator (37 °C / 5% CO2). After the 
incubation, trypsin was inactivated by addition of at least the same amount of the 
culture medium. The suspension was thoroughly resuspended and split or used for 
further purposes. 
For microscopy, the cells were counted in the Bürker chamber, accordingly to the 
manufacturer´s.  
 
4.1.3. Preparation and characterization of rho0 cells  
Cells were deprived of mtDNA by cultivation of parental cells in presence of sub-
lethal concentrations (50 ng/ml) of ethidium bromide (EtBr) for at least 3 months. 
After the EtBr treatment characterization of rho0 cells was performed by measuring 
respiration using the Oxygraph-2k respirometer. Compared to parental cells, rho0 
cells are unable to respire using the ETC. Therefore, the level of transcripts encoded 
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by mitochondrial DNA using qPCR was determine in Rho0 cells, as is described in 
chapter 4.14 in detail.  
 
4.1.4. Transfection of B16 cell lines 
B16 and B16 rho0 cells were transfected with the pTagBFP-H2B vector, described 
in Figure 4.1, to prepare cells, that permanently express the blue fluorescent protein 
(BFP) in the nucleus. The vector 12B triggers a BFP tag that is bound to the H2B 
region in the plasmid. To transfect the plasmid into the cells, a FuGENE® HD 
Transfection Reagent was used. Subsequently the selection of non-transfected cells 
was done using G418-sulfate antibiotics (0,4 mg/ml for 14 days).  
 
FIGURE 4.1: The map of pTagBFP-H2B vector (Evrogen) used for fluorescent labeling of 
histone H2B in live cells. (http://evrogen.com/vector-descriptions/pTagBFP-H2B/pTagBFP-
H2B.pdf) 
 
4.2. Isolation and cultivation of MSCs  
4.2.1. Isolation of mouse bone marrow MSCs 
Mice up to 20 weeks of age were sacrificed by cervical dislocation and rinsed in 70% 
ethanol for disinfection. The skin from the hind and fore limbs were removed and 
the limbs were dissected. All the adherent tissues (muscles and tendons) were 
carefully cleaned from the bones using the scalpel. Clean tibiae, femora and humeri 
were kept in the isolation buffer for one hour. After incubation in the isolation 
buffer, bones were cut and the bone marrow was rinsed out with the complete 
MesenCult™ basal medium (Mouse) using a 5ml syringe with 23G 0,6 x 30mm needle 
and collected in the falcon tubes. The bone cavities were thoroughly washed at least 
three times until the bones changed their colour from red to white. Collected bone 
marrow was then centrifuged at 300x g for 5 min. The pellets were resuspended in 
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fresh complete MesenCult™ basal medium (Mouse) with the addition of 
MesenPure™ and seeded in T75 flasks containing 15 ml of media. The whole 
procedure of MSCs isolation is shown in Figure 4.2.  
 
FIGURE 4.2: Isolation and culture of MSCs from mouse compact bone. A mouse disinfected 
by ethanol (A), skinning (B), isolated hind limbs (C), femora and humeri with removed adherent 
tissue (D), bones with and without joint heads (E), rinsing out of the bone marrow (F), 
established primary culture of MSCs (G). 
 
4.2.2. Cultivation of MSCs  
The culture of isolated MSCs was kept in humified incubator (37 °C / 5% CO2) for 4-
7 days depending on the confluency. After obtaining a confluent culture in passage 
0, all non-adherent cells were washed out from the flask with PBS. MSCs were then 
incubated for approximately 10 minutes with 0,25 % w/v solution of trypsin in PBS. 
After trypsinization 4 ml of the MesenCult™ basal medium (Mouse) was added and 
the cell suspension was plated at the 1:2 ratio into fresh T75 flasks and the cells 
were grown till confluence. The experiments were performed using MSCs between 
the third end ninth passage.   
 
4.3. Tumour generation and isolation 
The mice used for the grafting experiments were healthy, 10 weeks old animals with 
no sign of stress or discomfort. All animal procedures and experimental protocols 
were approved by the Animal Welfare Committee of the Czech Academy of Sciences.  
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4.3.1. Cancer cells injection  
The cells were trypsinized and counted in the Bürker chamber according to protocol 
mentioned in sections 4.1.2. and 4.1.3. The mice were then grafted subcutaneously 
(s.c.) above the right hind limb with various cell lines at 5 × 105 cells per animal into 
groups of 5-6 mice. 
 
4.3.2. Tumour isolation and primary culture establishment 
At the end of experiment, the mice were sacrificed, and the pre-tumour lesions or 
tumours were removed under sterile conditions. The tumour tissue was 
mechanically, or even enzymatically disintegrated. The pre-tumour lesion derived 
from B16 rho0 cells was resected and digested enzymatically (collagenase (250 
ng/ml) / DNase (50 ng/ml), 20 min, 37°C). 4T1 sub-lines were selected from tumour 
by treatment with 6-thioguanine (6TG) as described (Tan et al. 2015). The isolated 
cells were used to establish primary sub-lines for further study and were cultivated 
in the presence of 1 mM pyruvate and 50 mg/ml uridine. 
 
4.4. Tumour growth evaluation  
Tumour growth was monitored twice a week by ultrasound imaging using a Vevo 
770 instruments (FUJIFILM VisualSonics). Mice were anesthetized by the 
isoflurane-oxygen inhalation and then maintained in the anaesthetic state on the 
heated platform. The area, where the tumour cells were grafted, was shaved, and 
tumours were scanned with RMV704 or RMV708 scan-heads at 25-55 MHz. The 
acquired data were further processed using specific software. 
 
4.5. Preparation of samples for microscopy 
4.5.1. Standard samples  
Life-cell samples 
Cells were seeded into Petri dishe with glass bottom and incubated overnight. The 
next day the Mitotracker or live-cell staining was applied, and the cells were 
observed in a microscope.  
 
Fixed samples 
Cells were seeded on high precision cover slips at the to reach the final density and 
grown overnight. The cells were washed twice with PBS and fixed for 10 minutes in 
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4% paraformaldehyde. Fixed cells were permeabilized by washing in Wash Buffer 
three times for 10 minutes. After permeabilization the cells, unspecific signal was 
blocked by incubated in 300 µl of the 5% normal goat serum (5% NGS) for 30 
minutes. After washing with PBS cells were incubated overnight with primary 
antibodies.  
The next day, cover slips were washed three times for 10 minutes in Wash Buffer 
and incubated for 1 hour in secondary antibodies. After incubation, cells were 
washed three times with PBS for 10 minutes, once with H2O and were left to dry in 
dark. Dry cover slips were mounted to the microscope slides 76x26x1mm with 4 µl 
of mounting media and fixed by sealing the edges with transparent nail polish.  
 
Fixed samples of tissue sections for immunohistochemistry 
Isolated tumour tissue was fixed and embedded in paraffin blocks. It was cut into 
7μm sections on semi-automated rotary microtome (HistoCore MULTICUT, Leica 
Biosystems). The sections were deparaffined, rehydrated and the antigen were 
restored by heating in 10mM citrate buffer. Subsequently the samples were blocked 
with 10% NGS and labelled with Anti-Ki67 primary antibody. AlexaFluor 594 was 
used as a secondary antibody. Samples were mounted in VECTASHIELD® Antifade 
Mounting Medium with DAPI and the signal was detected on fluorescence 
microscope Nikon Eclipse E400. 
 
4.6. Microfluidic PDMS stamp  
4.6.1. Preparation of the PDMS stamp  
Polydimethylsiloxane (PDMS) was prepared using a SYLGARD® 184 kit by mixing 
a silicone elastomer base (monomer) with a silicone elastomer curing agent. The 
reagents were mixed up carefully for at least 5 minutes. The arisen bubbles were 
drained by a brief centrifugation. The unpolymerized PDMS was applied on the 
master mold (Figure 4.3 – A) in line around the negative pattern as a barrier (Figure 
4.3 – B). This barrier allowed to polymerize into the solid polymer on a hot plate 
prewarmed at 150 °C. The area defined by the barrier was evenly filled with the 
remaining PDMS. To remove any air bubbles left in the unpolymerized PDMS, it is 
necessary to place the whole form in a petri dish for 30 minutes to an hour in the 
desiccator (Figure 4.3 – C) and let the air bubbles disappear (Figure 4.3 – D). 
Subsequently, the master mould was transferred once again to the hot plate 
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prewarmed to 150 °C where the PDMS polymerized for about 5 minutes (Figure 4.3 
– E). After cooling, the polymerized PDMS (Figure 4.3 – F) was transferred to a 
sterile petri dish in the flow box. The holes for pipetting the cells were made with 
the punch needle into the polymer at the points of inlets and outlets (Figure 4.3 – 
G). Finally, the individual chips were cut from the polymerized PDMS. The chip 
surface was hydrophilized by glow discharge plasma before use. 
 
 
 
Figure 4.3: Scheme of photolithography. A reverse mould is created by shining a UV light 
through a mask, which cures a photosensitive epoxy resist below it (1). When the uncured 
photoresist is washed away, this leaves a master mould (2) with which a polydimethylsiloxane 
(PDMS) stamp is created (3,4). (http://biomechanicalregulation-lab.org/photolithography/) 
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4.6.2. Preparation of co-culture samples for microscopy in PDMS stamp device  
Life-cell samples 
The petri dish was treated with poly-L-lysine for 10 minutes. After plasma discharge 
treatment, the PDMS stamp was attached to bottom of the petri dish and cells were 
pipetted into the microfluidic chip as was described in the section 4.4.2.1. The cells 
were incubated overnight in the chip. Next day the chip was removed and cells were 
observed using confocal microscope.  
 
Fixed samples  
The high precision cover slips were treated with poly-L-lysine for 10 minutes. After 
plasma discharge treatment the PDMS stamp was attached to the cover slip. Two 
cell lines were pipetted into different channels of microfluidic chip through the 
inlets. The cells were incubated in the microfluidic chip overnight. The next day the 
PDMS stamp was removed. After next 24 hours cells were fixed as described in the 
section 4.5.1.1.  
 
4.7. Microscopy 
Microscopy experiments were done in the Imaging Methods Core Facility in BIOCEV 
or Institute of Molecular Genetics (IMG) with a help of Mgr. Marie Olšinová PhD., 
Mgr. Ivan Novotný PhD., Mgr. Markéta Dalecká and most of all with help of Mgr. 
Jaromíra Kovářová PhD.  
4.7.1. Confocal microscopy 
All confocal images of B16 sub-lines were acquired using Leica TCS SP5 AOBS 
Tandem (Obj. HCX PL APO 63x/1,30 GLYC CORR. 37°C) confocal microscope 
equipped with the LAS AF software. Confocal images of the 4T1 sub-lines and co-
cultures were acquired using Leica SP8 SMD-FLIM (objective: HC PL APO 63x/1.2 W 
Corr CS2) confocal inverted microscope.   
 
4.7.2. Stimulated emission depletion (STED) microscopy   
The B16 sub-lines samples were visualized using Leica TCS SP8 STED 3X 
microscope equipped with 660 nm STED depletion laser and fitted with the LAS X 
64 bit package software with LAS AF SP8 Dye Finder, 3D visualization, 
deconvolution and co-localization module. The STED images of 4T1 sub-lines were 
acquired on Abberior STED 775 QUAD Scanning microscope equipped with Nikon 
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CFI Plan Apo Lambda objective (60x Oil, NA 1.40). The labelled proteins were 
illuminated by pulsed 561 nm and 640 nm lasers and depleted by pulsed 775 nm 
STED depletion laser of 2D donut. 
 
4.7.3. Correlative light electron microscopy (CLEM) microscopy   
The cells were seeded into gridded 35 mm dish with glass bottom (MatTek 
Corporation) and after 24 hours were labelled with MitoTracker (250 nM, 30 min) 
and SirTubulin (1:1000 diluted, 1 hour) and prefixed with a mix of PFA and 
glutaraldehyde. For light microscopy, confocal and DIC images were acquired using 
Leica SP8 SMD-FLIM (Obj. HC PL APO 63x/1.2 W Corr CS2) confocal inverted 
microscope. Whole specimens were viewed using the Tile Scan function, and the 
positions of TNTs connecting two cells were localized. The coordinates of the TNTs 
in the specimen were noted based on the grid of the MatTek dish. After light 
microscopy data acquisition, the cells were post-fixed with osmium tetroxide, then 
dehydrated in ethanol series and embedded in epoxy resin. Subsequently, the areas 
of interest have been identified according to the grid imprinted into the block and 
visualized by focused ion beam – scanning electron microscopy FIB-SEM. The FIB-
SEM data were acquired using FIB-SEM DualBeam microscope FEI Helios NanoLab 
660 G3 UC. 
 
Figure 4.4: Focused ion beam scanning electron microscopy (FIB-SEM). Milling with a 
focused ion beam (blue) and imaging are performed within a dual-beam SEM (pink) (Romero-
Brey and Bartenschlager 2015) . 
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4.7.4. Microscopy images evaluation and post-processing 
The confocal and STED images were stabilized for drift and deconvolved with 
Huygens Professional version software 17.04 (Scientific Volume Imaging) using 
Classic Maximum Likelihood Estimation algorithm and processed by FiJi ImageJ 
software. The CLEM/FIB-SEM data were analyzed using Amira 6 software.  
 
4.8. Evaluation of mtDNA level  
Total DNA was extracted using the Wizard® Genomic DNA Purification Kit 
(Promega). 50 ng of DNA was subsequently diluted in water to total volume 4.5 μl, 
and 0.5 μl of the combined 10 mM forward and reverse primers added (for mtDNA, 
mMito1 primers; for nDNA mB2M1 primers). Then 5 μl of 2xRT2 SYBR Green qPCR 
Mastermix (Qiagen) were added and the reaction was run on the Eco qPCR System 
(Illumina). The setting of Eco qPCR is described in (Bajzikova et al. 2019).  
 
4.9. Evaluation of protein level  
For the evaluation of protein level Pierce™ BCA Protein Assay (ThermoFisher) was 
used according to manufacturer´s protocol.  
 
4.10. Evaluation of ATP level 
ATP was determined in cells seeded at 104 per well in 96-well plates in medium 
contained either 4.5 g/L glucose and 50 mM or no 2DG, which acts as it acts as a 
competitive inhibitor of glucose-6-phosphate production by glycolysis. The results 
were evaluated using a luciferase-based assay (CellTiter-Glo Luminescent Assay, 
Promega) and normalized to the total protein level in cell lysates assessed by the 
BCA method described above. 
 
4.11. Evaluation of NADH/NAD+ ratio  
The 4T1 parental and rho0 cells were seeded at concentration 1.5 x 104 per well in 
white-walled 96-well plates. The NADH/NAD+ ratio was evaluated using the 
bioluminescent NADH/NAD+ Glo Assay (Promega). Luminescence intensity was 
acquired with a Tecan Infinite M200 microplate reader. 
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4.12. Statistical analysis   
Presented data are mean values ± SEM of at least three independent measurements 
provided in triplicates. In mouse experiments, groups of 5-6 animals were used. 
Two-way Anova was used for multiple comparisons where applicable, using 
GraphPad Prism software. Images from microscopy are representative of three 
independent experiments.  
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5. Results  
5.1. Restoration of mtDNA in B16 rho0 cells mediated by the transfer 
of intact mitochondria  
Tan et al. have shown in their work B16 rho0 cells, that were injected s.c. into 
syngeneic C57BL/6J mice formed tumours with a 2–3-week delay compared to 
parental B16 cells. Next generation sequencing confirmed the host origin of mtDNA 
in the primary tumour cells grown from the original rho0 cells. (Tan et al. 2015).  
 
5.1.1. Stable Transfection of B16 rho0 cells  
B16 and mtDNA deficient B16rho0 cells were stably transfected with the 
mammalian expression vector pTagBFP-H2B (Evrogen) encoding TagBFP-H2B 
fusion protein. The vector backbone contains among others the immediate early 
promoter of cytomegalovirus (PCMV IE) for protein expression and the SV40 origin for 
replication in mammalian cells expressing the SV40 T-antigen. The SV40 early 
promoter (PSV40) provides neomycin resistance gene (Neor) expression to select 
stably transfected eukaryotic cells using G418. B16 and B16 rho0 BFP positive cells 
were then examined by confocal microscope together with un-transfected B16 rho0 
cells, which were used here as non-fluorescence control. The confocal images shown 
below document a successful transfection and the expression of BFP in the nuclei of 
the appropriate cell lines. 
 
FIGURE 5.1.: Morphology of B16 parental cells and derived B16 rho0 and B16 rho0 DP cell lines 
was observed by Leica DMIL LED microscope and the images were processed in LAS v4.5 
software (A). The transfected cells were observed in FluoroBrite™ DMEM Medium using Leica 
TCS SP5 AOBS Tandem confocal microscope (Obj. HCX PL APO 63x/1,30 GLYC CORR.) equipped 
with the LAS AF software (B). Figure 5.1. – B shows deconvolved images of one plane.  
B16 B16 ρ0 B16 ρ0 DP 
100 μm 
A 
B16 rho0 B16 rho0 BFP+ 
 
B16 rho0 BFP+/dsRed+ B16 BFP+  
 
10 μm 
B 
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5.1.2. Transfer of mitochondria from donor cells to recipient B16 rho0 cells in vivo 
Transgenic C57BL/6Nsu9-DsRed2 mice with dsRed  fluorescent mitochondria were 
used to observe the transfer of mitochondria in vivo. B16 rho0 cells were transfected 
with a plasmid expressing blue fluorescent protein targeting nuclei (nBFP) and 
subsequently   injected s.c. into C57BL/6Nsu9DsRed2 mice. 11 days later the mice were 
sacrificed, and the pre-tumour lesion was isolated. The tumour tissue was 
enzymatically disintegrated into single cell suspension which was then sorted for 
the double positive (DP) cell population. The DP B16 rho0 cell population reported 
both fluorescence signals – BFP signal from the recipient cell nucleus and dsRed 
signal from the host cell mitochondria. In the tumour single cell suspension, 0.52% 
were formed by the double-positive (BFP+/dsRed+) cell population. The sorted DP 
B16 rho0 cells were immediately allowed to attach and inspected by confocal 
microscope several hours later. The microscopy results shown in 5.2 document the 
transfer of mitochondria from host somatic cells to tumour cells with depleted 
mtDNA, showing both fluorescent signals (BFP and dsRed) within a single B16 rho0 
cell.   
 
FIGURE 5.2: In vivo detection of mitochondrial transfer from donor MSC cells to recipient 
B16 rho0 cells. Transgenic mice with dsRed labelled mitochondria were s.c. injected with 106 
B16 rho0 cells, that stably expressing nBFP. 11 days later a mouse was sacrificed, the tumour 
tissue was digested into a single-cell population and sorted for DP cells, containing blue 
fluorescent nuclei and red fluorescent mitochondria. The sorted cells were allowed to attach 
and subsequently observed by confocal microscope. The image was acquired on Leica TCS SP5 
AOBS Tandem confocal microscope (Obj. HC PL APO 63x/1,40 OIL, CS2) equipped with the LAS 
AF software. and shows maximum intensity Z-projection of a representative DP cell. These data 
were published by Dong et al., 2017. 
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5.1.3. Tumour formation capacity of parental B16 and B16 rho0 cells  
B16 parental, rho0 and the tumour derived rho0 DP cells were grafted s.c. into 
syngeneic mice to investigate the capacity of the individual cell-lines to form 
tumours.  The rho0 cells started to form the tumours with almost 3-week delay 
compared with parental cells, while the rho0 DP cells were much more aggressive 
and formed tumours at the same time interval as the parental cells. The tumours 
(FUJIFILM VisualSonics).  
 
 
FIGURE 5.3: Comparison of growth curves of tumours derived from parental, rho0 and 
rho0 DP B16 melanoma cancer cells.  B16 cells and their rho0 and rho0 DP counterparts 
were grafted s.c. into syngeneic mice. The graph shows data from three independent 
measurements and the results are expressed as mean ± SEM. The tumour growth curves were 
published by Dong et. al, 2017 
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5.1.4. Evaluation of ATP levels in B16 sub-lines  
B16 sub-lines were analysed for ATP levels in the absence and presence of 50 mM 
2DG in glucose containing DMEM medium (4.5 g/L glucose) supplemented with 50 
mg/ml uridine and 1 mM pyruvate using a luciferase-based ATP detection kit and a 
microplate reader. The results were normalized to the total protein level in cell 
lysates. The results shown in Figure 5.4 indicate that glycolysis contributed to ATP 
generation with 50% in parental and rho0 DP cells, where mitochondrial transfer 
predated, whereas in rho0 cells glycolysis contributed to ATP generation by 100%, 
since these cells provide no OXPHOS. 
 
FIGURE 5.4: ATP level was determined in B16 sub-lines. B16, B16 rho0 and B16 rho0 DP 
cells were seeded each at a concentration of 104 per 100 ul per well in white walled 96-well 
plates using a luciferase-based assay. Tecan Infinitive M200 microplate reader was used to 
measure luminescence. The graph shows data from three independent measurements and the 
results are expressed as mean ± SEM (Adjusted P values – '*' = 0,0118; '***' = 0,0008; '****' 
<0,0001)   
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5.1.5. Determination of mtDNA content in B16 sub-lines by STED microscopy 
B16, B16 rho0 and the established B16 rho0 DP cell lines were immunostained for 
DNA and mitochondrial transcription factor A (TFAM) or mitochondrial import 
receptor subunit (TOMM20) and observed by STED microscopy to determine the 
content of mtDNA in form of mitochondrial nucleoids.  The results shown in 
representative micrographs below support the previous results showing similar 
levels of mtDNA in both – parental and rho0 DP cells, while no mitochondrial DNA 
as well as TFAM signal could be detected in B16 rho0 cells. The STED images also 
confirm the localisation of mitochondrial nucleoids within the mitochondria and 
their co-localisation with the TFAM protein, which binds to mitochondrial DNA and 
which is involved in maintenance and processing of mtDNA as well as packaging of 
mtDNA into mt-nucleoids.  
 
 
 
 
 
 
A 
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FIGURE 5.5: Distribution of mitochondrial nucleoids in B16 sub-lines. B16, B16 rho0 and 
B16 rho0 DP cells were co-stained for mitochondrial DNA (shown in red) and TOMM20 (A) or 
TFAM (B) protein (shown in green). The upper panels show the majority of individual cells 
while the lower panels represent a higher magnification of the region of interest indicated by 
the yellow boxes.  TOMM20 and TFAM were stained with Alexa Fluor488 goat anti-rabbit IgG 
secondary antibody and DNA was stained with Alexa Fluor555 goat anti-mouse IgM secondary 
antibody. The cell nuclei were labelled with Hoechst 33342.  The samples were visualized using 
Leica TCS SP8 STED 3X microscope equipped with 660 nm depletion laser and the LAS X 64 bit 
package software with LAS AF SP8 Dye Finder. These micrographs were published by Dong et 
al., 2017. 
 
5.2. Characterisation of the initial phase of primary tumour formation     
To characterise the period of the initial tumour growth dormancy, the cells isolated 
at different time points from the primary tumours formed from the original rho0 
cells were investigated in detail. The relevant experiments were carried out using 
4T1 derived sub-lines. 
4T1 rho0 cells were grafted s.c. into Balb/c mice in a concentration of 106 cells per 
100 ul PBS per mouse. The formed tumours were excised on days 5, 10, 15, 20, 25 
and 60, whereby 5-6 animals were used in each time point. The cancer cells were 
subsequently isolated from the primary tumour tissue and cultivated in the 
presence of 6-TG as described by Tan et al. 2015 (Tan et al. 2015).  
 
B 
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5.2.1. Tumour formation capacity of parental 4T1 and 4T1 rho0 cells  
4T1 parental and the derived rho0 cells were grafted s.c. into syngeneic mice. The 
rho0 cells started to form the tumours with a with a lag of 3 week compared to the 
parental cells, with noticeable tumours appearing on day 20–25. The tumours were 
monitored, and their volume calculated using the USI device Vevo770 (FUJIFILM 
VisualSonics) (Figure 5.6 – B). The experiments were terminated when the tumour 
volume reached a size of about 1 000 mm3. Delayed tumour formation suggests that 
the preceding mitochondrial transfer and the subsequent restoration of 
mitochondrial functions are essential for tumour formation initiation. 
 
 
FIGURE 5.6: Tumour formation ability of 4T1 parental and rho0 breast cancer cells.  4T1 
cells and their and their rho0 derived sub-line were grafted into Balb/c mice and the tumour 
growth was monitored by Vevo770 USI (B). The above graph of tumour growth curves (A) 
shows data from three independent measurements and the results are expressed as mean ± 
SEM. The curves of tumour growth were published by Bajzikova et al., 2019. 
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5.2.2. Evaluation of cell proliferation in tumour tissue  
Parental 4T1 and 4T1 rho0 derived tumours were fixed with PFA and embedded in 
paraffin blocks. Subsequently, immunohistochemical tissue sections stained for 
Ki67 were prepared. Figure 5.7 shows gradually increasing Ki67 signal linked to cell 
proliferation between rho0 D5 and rho0 D15 tumours and a similar proliferation 
rate in rho0 D20 and rho0 D25 tumours as observed for the parental 4T1 tumours.  
These data correspond with the delay in tumour formation shown in Figure 5.6. 
 
FIGURE 5.7: Proliferating cells in 4T1 derived tumour tissue sections visualised by Ki-67 
primary and AlexaFluor 594 secondary antibody. The samples were observed with 
fluorescence microscope Nikon Eclipse E400 (CFI PL APO DM40X OIL). The numbers in the right 
bottom corner indicate percentage of Ki67-positive cells in each sub-line. The presented 
fluorescence images are representative of three micrographs. These data were published by 
Bajzikova et al. 2019.   
52 
 
5.2.3. Morphology and growth of 4T1 sub-lines in normal medium and medium 
supplemented with 2-DG 
Parental 4T1 cells and cells derived from primary 4T1 rho0 tumours at different 
time points were cultivated for 24 h in medium supplemented with 50 mM 2-DG. 2-
DG is a glycolytic inhibitor. The results documented in fig. 5.8 indicate that rho0 cells 
and the derived cells with lower mtDNA content are more sensitive to the effects of 
2-DG in contrast to the parental 4T1 cells and cells with higher mtDNA content. 
These data correspond with the mtDNA levels measured by Bajzíková et al 
(Bajzikova et al. 2019). 
 
FIGURE 5.8: Comparison of cellular morphology of cells cultivated in standard 4T1 rho0 
medium and in 4T1 rho0 medium supplemented with 50 mM 2-DG. 
The 4T1 sub-lines (4T1, 4T1 rho0 and 4T1 rho0 D5-D60) were cultivated for 24 h either in 4T1 
rho0 medium or in 4T1 rho0 medium supplemented with 2-DG and subsequently live cell 
images were obtained by Leica DMIL LED microscope and the images were processed in LAS 
v4.5 software. The presented images are representative of three.   
D60 
53 
 
5.2.4. Evaluation of ATP levels an NADH/NAD+ ratio in tumour derived 4T1 sub-
lines 
Individual tumour derived cell lines were evaluated for ATP levels in in medium 
containing 50 mM 2DG at 4.5 g/L glucose, supplemented with 50 mg/ml uridine and 
1 mM pyruvate, and the results were expressed relative to total ATP in parental 
cells. The results presented in Fig. 5.9 are relative to total ATP/protein ratio in 
parental 4T1 cells and they document that glycolysis contributed to ATP generation 
by ≈30% in parental and 90% in D0–D10 cells. 
 
 
FIGURE 5.9: Relative ATP/protein ratio was determined in the 4T1 sub-lines seeded at a 
concentration of 104 cells per 100 ul and well in white walled 96-well plates using a luciferase-
based assay. Tecan Infinitive M200 microplate reader was used to measure luminescence. The 
graph shows data from three independent measurements and the results are expressed as mean 
± SEM (Adjusted P values –'****' <0,0001). These data were adapted from Bajzikova et al., 2019. 
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Oxidized and reduced nicotinamide adenine dinucleotides (NAD+ and NADH) were 
assessed in the 4T1 tumour-derived cell lines by a commercial luciferase-based 
assay and a microplate reader. The NADH/NAD+ ratios measured in the individual 
tumour-derived 4T1 sub-lines confirmed the tendency of the cells to return to basal 
respiration levels as measured for the parental 4T1 cells. These data correspond 
with the respiration levels measured by Bajzíková et al (Bajzikova et al. 2019). 
 
FIGURE 5.10: NADH/NAD+ ratio was investigated in 4T1 sub-lines using a luminescence-
based assay and a Tecan Infinite M200 microplate reader was used to measure luminescence. 
The graph shows data from three independent experiments and the results are expressed as 
mean ± SEM (Adjusted P values – '* 1' = 0,0288; '* 2' = 0,0181; '**' = 0,0097). These data were 
published by Bajzikova et al., 2019. 
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5.2.5. Visualisation of mtDNA distribution in form of mt-nucleoids in the analysed 
4T1 sub-lines by STED microscopy 
The individual sub-lines derived at different time points from the primary tumours 
grown from the 4T1 rho0 cells were further studied for their mtDNA distribution. 
The cells were immunostained for DNA and mitochondrial transcription factor A 
(TFAM) or DNA and mitochondrial import receptor subunit (TOMM20) and 
inspected by STED microscopy to determine the content of mtDNA in mitochondrial 
nucleoids. Representative micrographs shown in Fig. 5.11 support the above 
described results. The number of mt-nucleoids is gradually increasing from rho0 D5 
to rho0 D15 cells. Cells isolated from rho0 D20 – rho0 D60 tumours provide a 
comparable level of mt-nucleoids as documented for the parental 4T1 cells. As 
expected, the 4T1 rho0 cells do not contain mtDNA and thus they show reduced 
levels of TFAM protein, which cannot bind to mtDNA.   
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FIGURE 5.11: Distribution of mitochondrial nucleoids in 4T1 sub-lines. Mitochondrial 
proteins TOMM20 (A) and TFAM (B) were stained by immunofluorescence and the 
representative micrographs above show the co-localization with DNA staining, which 
represents the mtDNA of mitochondrial nucleoids. The upper panels show the majority of 
individual cells while the lower panels represent a higher magnification of the region of interest 
indicated by the yellow boxes. TOMM20 and TFAM were stained with Abberior STAR 580 goat 
ant-rabbit IgG secondary antibody and DNA was stained with Abberior STAR RED goat anti-
mouse IgG. Nuclei were labelled with Hoechst 33342. Labelled samples were illuminated by 
pulsed 561 nm and 640 nm lasers and depleted by pulsed 775 nm STED depletion laser of 2D 
donut, using Abberior Instruments STED microscope. The maximal intensity projection of 500 
nm Z-stack is shown. These micrographs were published by Bajzikova et al., 2019. 
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5.3. Intercellular transfer of intact mitochondria 
5.3.1. Mitochondrial transfer mediated through TNTs studied in a in vitro co-
culture system 
The stably transfected 4T1 rho0 cells expressing GFP in plasma membrane and BFP 
in nuclei were co-cultivated with MSCs expressing dsRed protein in mitochondria 
for 24 h. The cells were subsequently fixed with 4% PFA, permeabilised and stained 
for alpha-tubulin. The representative confocal image shown in Fig. 5.12 documents 
the transfer of intact mitochondria mediated by the TNT structure interconnecting 
the rho0 cell that expresses GFP (green) in its plasma membrane and BFP in cell 
nucleus with a MSC, which expresses dsRed fluorescent protein in its mitochondria 
(red). The yellow box represents a higher magnification of the region of interest, 
showing a TNT section containing tubulin fibres with aligned dsRed fluorescent 
mitochondria. This indicates the possible role of microtubules in mitochondrial 
transfer. Most importantly, the dsRed positive mitochondria can also be detected in 
the original 4T1 rho0 cell stably expressing GFP in its plasma membrane and BFP in 
the nucleus. The observed phenomenon documents the transfer of mitochondria 
from a MSC into a rho0 cell. 
 
FIGURE 5.12: Mitochondrial transfer in co-culture of 4T1 rho0 pmGFP/nBFP and dsRed 
MSCs. The cells were fixed and permeabilised and alpha tubulin was visualised using an Anti-
alpha-tubulin primary antibody and the appropriate AlexaFluor 647 secondary antibody 
(gray). The nuclei were stained with Hoechst 33342 (blue). The co-culture was observed by 
Leica SP8 SMD-FLIM confocal microscope using (Obj. HC PL APO CS2 63x OIL). The image shows 
maximal intensity projection (MIP) and was deconvolved using the Huygens Professional 
software - version software 17.04 (Scientific Volume Imaging). One representative image of 
three independent experiments is shown. 
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5.3.2. Mitochondrial transfer by TNTs in co-cultures using microfluidic PDMS chip 
In a co-culture system consisting of two different cell types an enormous disorder 
predominates. To get control over the system and to be able to easily detect TNTs 
formed between the two cell types a special microfluidic PDMS stamp was 
developed consisting of two channels separated by an inter-channel space.   
4T1 rho0 cells stably expressing diffuse GFP in their cytoplasm were seeded at 1,5 
x 104 cells/μl in one channel of the microfluidic device while MSCs expressing dsRed 
fluorescent protein in their mitochondria were seeded in the second channel at the 
same concentration. The cells were allowed to attach to the coverslip surface 
overnight, then the device was removed and the cells, separated by the chip, were 
co-cultivated for further 24 h. The cells in the separated channel area as well as the 
inter-channel space were subsequently inspected for TNTs formed between both 
cell types. Fig. 5.13 documents the separation of the two different cell lines in two 
distinct channels in the PDMS stamp. The image does not show the inter-channel 
area with inter-connecting TNTs formed between the two different cell lines, since 
the developed co-culture device was at that time not fully operational and an 
optimalisation was required. This could not be achieved here due to the limited time 
of the diploma thesis.   
 
FIGURE 5.13: Controlled co-culture of dsRed fluorescent MSCs and 4T1 rho0 cells 
expressing GFP in cytoplasm seeded in a PDMS microfluidic device. The image shows the 
two separated channels in the microfluidic stamp device either with attached MSCs (red) or 
with 4T1 rho0 cells (green). The inter-channel area is not shown here. Representative image of 
three was acquired by Leica SP8 SMD-FLIM confocal microscope (Obj. HC PL APO CS2 63x WI) 
and shows the maximal intensity projection of a 500 nm Z-stack.  
DIC GFP merge 
DIC merge dsRed 
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5.3.3. Reconstruction of 3D structure of TNTs by CLEM/FIB-SEM 
The next part of the work focused on the analysis of the 3D structure of a TNT 
formed between rho0 cancer cell and MSC. CLEM/FIB-SEM should also provide 
information about the mechanism and regulation of mitochondrial transfer, 
whether mitochondria are transported only in one way, i.e. from MSC towards rho0 
cell, or whether the transport proceeds in both directions. It should also obvious, 
whether the mitochondria within the analysed part of TNT contain cristae or not 
and weather they have prolonged or rounded shape and if they are localised on 
tubulin fibres during transfer.  
Since the PDMS co-culturing device was not completely established so far, the 
preliminary data were obtained using an MSC monoculture. 
The MSCs were cultivated in glass bottom MatTek dish with grid for 24 hours. 
Subsequently, living cells were stained with the fluorescence dyes SiR-Tubulin (for 
1 hour) and MitoTracker (for 30 minutes) and observed by confocal microscope. 
Then the cells were fixed with 2,5% GA and 1% PFA and again inspected by confocal 
microscope, as documented in Figures 5.14 and 5.15 – A. The area of interest 
showing two MSCs interconnected by a TNT is highlighted in DIC Tile-scan image 
(yellow box), in Figure 5.14. Figure 5.15 – A represents a micrograph with 
mitochondria fluorescently labelled by MitoTracker DeepRed (MTDR) (green) and 
alpha-tubulin fluorescently labelled by SiR-Tubulin (red) after fixation.  
Subsequently, the cells were post-fixed by osmium tetroxide, contrasted by uranyl 
acetate and dehydrated in ethanol series. Then the cells were embedded in epoxy 
resin, mounted on a SEM stub and a trench was removed in front of the area of 
interest. Finally, the specimen was milled with FIB and imaged with SEM in a 
sequential manner as long as the tomographic dataset was acquired, as displayed in 
Figure 4.4. Figure 5.15 – B represents the stacked image of a part of tunnelling 
nanotube shown in Figure 5.15 – A indicated in a yellow box. The yellow box in 
Figure 5.15 – B represents a cross-section of the TNT at the level of the 
mitochondrion no. 1, highlighted by the yellow arrow and number 1. Figure 5.15 – 
C represents a 3D reconstruction of the inner structure of the particular part of TNT. 
This image was generated by Amira 6 software using Volren function, that allows a 
volume rendering of the acquired data based on the density differentiation of 
individual structures. In contrast to Figure 5.15 – B, Figure 5.15 – C is rotated by 
90%, so that it can be viewed in the same orientation as the confocal microscope 
60 
 
image 5.15 – A. The black and yellow arrows with numbers in Figure 5.15 – A and – 
C indicate individual mitochondria in the particular TNT section. The results 
obtained by this experiment confirmed the presence of alpha-tubulin in the TNT 
structure formed between two MSCs. The data obtained by the FIB-SEM method 
were subsequently post-processed by Amira software and based on different 
densities, the 3D reconstruction of the selected TNT part was enabled.  
 
 
FIGURE 5.14: Confocal DIC tile-scan image of MSC monoculture showing the selected 
region of interest highlighted by yellow box. The image was acquired after fixation with 
2,5% GA and 1% PFA by Leica SP8 SMD-FLIM confocal microscope (Obj. HC PL APO CS2 63x 
WI) 
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FIGURE 5.15: Analysis of mitochondrial transfer mediated by TNT using CLEM/FIB-SEM. 
The image obtained by confocal microscopy shows MTDR labelled mitochondria (red) and SiR-
Tubulin labelled alpha-tubulin (red) (A). The composed image of a part of TNT was acquired 
by FIB-SEM, the yellow box represents a cross-section at the level of mitochondrion no.1, 
highlighted by the yellow arrow (B). 3D-reconsturction of the inner structure of the specific 
TNT part was created by the Volren function in Amira 6 software (C). The fluorescence 
microscopy was performed on the confocal microscope Leica TCS SP8 WLL SMD-FLIM (Obj. HC 
PL APO CS2 63x WI), the acquired confocal images were deconvolved using Huygens 
Professional version software 17.04 (Scientific Volume Imaging) and their maximal intensity 
projection was combined with FIB-SEM data acquired by FEI Helios NanoLab 660 G3 UC. Amira 
6 was used for post-processing of the FIB-SEM data. All presented images show one 
representative image of three independent experiments. 
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6. Discussion  
In last decades genome mutations and instability became one of the ten hallmarks 
of cancer since the understanding of the role of mutations in nuclear DNA in 
neoplastic diseases deepened thanks to whole-genome approaches (Khurana et al. 
2013, Hanahan and Weinberg 2011). Standard mammalian cells additionally 
contain thousands of copies of mitochondrial genome, which are organized in 
mtDNA-protein complexes known as mitochondrial nucleoids (Kukat et al. 2015).  
Several mechanisms maintain the integrity of mitochondria and mitochondrial 
genome in post-mitotic cells. Constant cycles of fusion and fission promote the 
mixing and the homogenization of mtDNA between discrete organelles within the 
same cell (Mishra and Chan 2014). Therefore, the mtDNA copies in the cells can be 
identical (homoplasmy) or may vary (heteroplasmy). Although it was generally 
assumed that healthy individuals exhibit homoplasmy for a single mtDNA genotype, 
next-generation sequencing revealed the presence of low-level heteroplasmy in 
most tissues from healthy individuals and the heteroplasmic mtDNA mutations 
present in the cancer cells help to deregulate the cellular bioenergetics (He et al. 
2010, Payne et al. 2013). Although, cells can tolerate a heavy load of pathogenic 
mutations, these can lead to disease when the mutation load surpasses a tolerable 
threshold (Wallace 2013). 
As described by Tseng et al. mtDNA mutations and low amounts of mtDNA copy 
numbers are associated with increased metastasis and poor prognosis in breast 
cancer (Tseng et al. 2006). Low mtDNA copy numbers seem to be also the promoting 
factor of EMT via mitochondrial retrograde signaling (Guha and Avadhani 2013), 
the cells with deleterious mtDNA mutations fail in tumor formation and mutations 
in the genes encoding proteins of OXPHOS restrain tumorigenesis (Weinberg et al. 
2010, Park et al. 2009) .  
In this work 4T1 and B16 rho0 cells were used as an extreme model of mtDNA 
damage. The mtDNA/nDNA ratio and oxygen consumption were characterized in 
these cells and significant differences were estimated. Unlike the parental cells, rho0 
cells do not contain mtDNA and do not respire through mitochondrial respiratory 
complexes (Dong et al. 2017, Tan et al. 2015). Transmission electron microscopy 
(TEM) revealed, differences in mitochondrial morphology between parental and 
rho0 cells, whereby 4T1 rho0 cells contain almost no cristae, when  compared with 
their parental counterparts (Tan et al. 2015). Similar mitochondrial morphology 
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was also observed for B16 cell sub-lines. Mitochondria of parental B16 and rho0 DP 
cells contain fully formed mitochondrial cristae, whereas rho0 cells show almost no 
cristae (Dong et al. 2017). 
The results from experiments on metastatic murine tumor models, shown in Figure 
5.4 and 5.7, confirmed the findings of Tan et al. Rho0 cell lines with depleted mtDNA 
exhibited delayed tumor formation in both B16 rho0 melanoma cells grafted s.c. into 
syngeneic C57BL/6 and in 4T1 rho0 breast cancer cells injected s.c. into Balb/c mice. 
Tan et al. further confirmed that delayed tumor growth was associated with mtDNA 
acquisition via mitochondrial transfer from host stromal cells. They demonstrated 
that tumors grown from B16 rho0 and 4T1 rho0 cells were positive for cytochrome 
b (Cytb), a gene that is encoded by mtDNA. Also, mitochondrial protein synthesis 
was shown to be functional in cell lines derived from tumors formed from B16 rho0 
and 4T1 rho0 cells by the presence of an mtDNA-encoded cytochrome c oxidase 
subunit 1 protein (COI). (Tan et al. 2015).  
To further explore the link between OXPHOS function and tumor formation a unique 
experimental model was developed. Tumors were excised from the mice in different 
time points – between 0-60 days, and the isolated cancer cells were subsequently 
characterized. The derived 4T1 rho0 sub-lines (D5-D60) were stable in cell culture 
over time, and their biological properties, such as the level of mtDNA, respiration, 
or ETC assembly, did not change with time, when cultivated in the cell culture media 
supplemented uridine/pyruvate. 
To find another evidence for mitochondrial DNA transfer in cells isolated from rho0 
cell-derived tumors, further experiments were designed. STED microscopy 
confirmed co-localization of mtDNA with mitochondrial proteins TOM20 and TFAM 
in B16 rho0 DP cells as well as increasing levels of mtDNA in 4T1 rho0 cell sub-lines 
D5-D60, as documented by Figure 5.6 and 5.12.  
The metabolic state of the rho0 cells and cells derived from rho0 tumors was 
established by a commercial assay measuring ATP levels in the cell sub-lines, shown 
in Figure 5.5 and 5.10. The results indicate similar bioenergetics between B16 rho0 
DP and parental B16 cells. Both cell types produced 50% ATP by glycolysis, whereas 
in B16 rho0 cells the entire ATP was generated through glycolysis. Corresponding 
results were observed for the 4T1 cell sub-lines. The sub-lines isolated from 4T1 
rho0 derived tumors showed high production of ATP by glycolysis in D5 and D10 
cells and increased levels of OXPHOS in the other derived sub-lines. 4T1 rho0 
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produced all the ATP by glycolysis, whereas 30% of ATP were produced by 
glycolysis in parental 4T1 cells. These results also correspond with the delayed 
tumor formation of 4T1 rho0 cells, as shown in Figure 5.7. 
The B16 rho0 cells seem to have higher requirements for the respiration recovery 
connected with tumor formation. The bioenergy threshold, which is apparently 
lower for 4T1 rho0 cells, might be caused by higher routine respiration of B16 cells 
(∼100 pmol O2/s/106 cells), while 4T1 cells provide five times lower routine 
respiration (∼20 pmol O2/s/106 cells) (Dong et al. 2017, Tan et al. 2015). In addition, 
the bioenergetic deregulation might also be the result of different genetic mutations 
in both B16 and 4T1 cell lines. It is still not clear, whether there is a link between 
these mutations and the need for respiration adjustment required for tumor 
initiation. 
Interesting results, related to the above-mentioned ATP levels, were observed when 
4T1 sub-lines were cultivated in medium supplemented with 50mM 2-deoxy-D-
glucose, as displayed in Figure 5.9. Rho0 cells as well as the cells with lower content 
of mtDNA (i.e. D5 and D10), were significantly more sensitive to the effects of 2DG, 
in comparison with the parental 4T1 cells and sub-lines with higher content of 
mtDNA (D15-D60). No differences were observed between all the tested sub-lines 
cultivated in 4T1 rho0 medium without additional 2DG. All these results correspond 
with the outcomes from NADH/NAD+ ratio measurements, which confirmed the 
respiration recovery linked to the tumor growth, shown in Figure 5.11. The same 
trend was documented by using the cell proliferation marker Ki-67 and 
immunohistochemical staining, as documented by Figure 5.8.  
Additionally, to the above-mentioned experiments, the aspects of OXPHOS function, 
which is essential for the initiation of tumorigenesis, were investigated. Surprisingly 
4T1 cells deficient in ATP synthase (ATP5β KO) were able to form tumors, when s.c. 
grafted into syngeneic mice. This finding points to the fact that production of ATP 
by ATP synthase, is not a limiting factor for tumorigenesis (Bajzikova et al. 2019). 
While ATP production was not essential, OXPHOS-related de novo pyrimidine 
synthesis, which is driven by respiration via DHODH was proven to be crucial for 
tumor formation. As described in Figure 1.6, there is a link between OXPHOS system 
and DHODH in the point of CoQ redox-cycling (Grégoire et al. 1984, Ayer, Macdonald 
and Stocker 2015). In healthy and fully respiring cells electrons are supplied to 
coenzyme Q through the CI, CII, and DHOH. From CoQ the electrons are transferred 
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to CIII, which forwards them to complex IV. Complexes I, III and IV increase the 
proton-motive force, that drives the ATP formation catalyzed by CV – ATP synthase. 
In the case of extremely damaged mtDNA, when a cancer cell is disabled to assemble 
functional complexes of ETC, there is no CIII activity and therefore the CoQ redox-
cycle is disrupted, whereby DHODH is not able to convert DHO into orotate. 
The importance of the link between OXPHOS and pyrimidine de novo synthesis was 
demonstrated on DHODH deficient cancer cells (DHODH KO), that failed in tumor 
formation, despite the fact that these cells provided the otherwise fully functional 
OXPHOS and normal ATP levels (Bajzikova et al. 2019). 
Taking together, these results confirm mitochondrial transfer in vivo and its 
importance for the tumorigenesis. On the other hand, a question arises, how mtDNA 
is acquired. Since no mechanism of mtDNA transfer through the outer and inner 
mitochondrial membranes and across the plasma membrane to another cell has 
been described in mammalian cells so far, the only possible ways for mitochondrial 
transfer are the transfer of intact mitochondria between two cells or mitochondria 
transmission by fusion of two cells. Recent literature describes both ways of 
mitochondrial transfer, selective transport of mitochondria (Tan et al. 2015, Dong 
et al. 2017) and cell fusion (Vitale et al. 2011). Mitochondrial transfer has been 
previously described in vitro (Spees et al. 2006, Gerdes and Carvalho 2008, Gurke et 
al. 2008, Cho et al. 2012) and in vivo in a murine model of acute lung injury (Islam 
et al. 2012).  
The most interesting evidence for in vivo mitochondrial transmission, which at the 
same time partially answers the previously formulated question about how mtDNA 
is acquired, is documented by the experiment, where B16 rho0 cells with BFP-
labeled nuclei were grafted into C57BL/6Nsu9DsRed2 mice expressing dsRed protein 
in mitochondria of somatic cells, shown in Figure 5.2. The mentioned experiment 
was designed to bring the evidence that intact mitochondria are transferred 
between somatic cells of host organism and grafted cancer cells with depleted 
mtDNA. This hypothesis of intact mitochondria transfer was verified by this 
experiment as well as by other experiments confirming long-term respiration 
recovery. Furthermore, mitoChIP analysis showed that the mitochondrial DNA 
polymerase subunit gamma (POLG1) binds strongly to the D-LOOP region of mtDNA 
in B16 rho0 DP cells as well as in parental B16 (Dong et al. 2017).  
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The transient nature of dsRed fluorescence affirms the fact that the intact 
mitochondria are transferred from the host cells. Since the dsRed protein is encoded 
by nuclear DNA of the donor cell, it cannot be replenished by de novo synthesis in 
the recipient cancer cell. The fluorescent signal of dsRed protein therefore depends 
on the fluorescence life-time of the protein and is gradually lost after the cell 
isolation from tumor. In case of cell fusion, the dsRed fluorescent signal would be 
stable. 
The next aim of this work was to explore the mechanism by which are mitochondria 
transferred between cells. Since tunneling nanotubes seem to be a plausible form of 
intercellular transfer of organelles (Rustom et al. 2004, Rustom 2016, Rogers and 
Bhattacharya 2013) the diploma thesis also focuses on this mechanism. The 
experimental tools here were represented by 4T1 rho0 cells, an experimental model 
of bioenergetically deregulated acceptor cancer cells and MSCs, the donator somatic 
cells with functional mitochondrial bioenergetics. MSCs have been described 
previously as donors of mitochondria in range of experiments using models of 
mitochondrial damage (Spees et al. 2006, Li et al. 2014, He et al. 2011, Liu et al. 2014, 
Plotnikov et al. 2010, Oh et al. 2003, Islam et al. 2012, Acquistapace et al. 2011). 
One of the possible ways, how to explore intercellular mitochondrial transfer is the 
usage of advanced imaging techniques including confocal, STED and FIB-SEM 
microscopy. In these experiments MSCs, expressing dsRed fluorescent protein in 
mitochondria, were co-cultivated with 4T1 rho0 cells expressing diffuse GFP in 
cytoplasm, plasmatic membrane or in mitochondria. Mesenchymal stem cells tend 
to form rich protrusions in vitro and they cross-link with rho0 cancer cells through 
their protrusions – tunneling nanotubes in a co-culture, as shown in Figure 5.13.  
Recent literature is not uniform in the view of cytoskeletal equipment of TNTs 
(Ariazi et al. 2017, Resnik et al. 2018). Confocal microscopy used in this work 
confirms, that the TNTs formed between MSCs and rho0 cancer cells are tubulin-
based. Furthermore, co-localization of alpha-tubulin and dsRed labeled 
mitochondria assumes that mitochondrial transfer is mediated by the movement of 
molecular motors along microtubule fibers. The transferred dsRed mitochondria 
can also be found in recipient GFP labeled 4T1 rho0 cell as documented in Figure 
5.13.   
The complication of co-culture experiments represents the uncontrollable 
orientation in the cell types mixture. Therefore, this work introduces a new co-
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cultivation system. It makes use of a PDMS microfluidic chip, where two cell types 
are seeded separately, shown in Figure 5.14. After removing the PDMS stamp the 
cells remain attached to the glass surface in precisely defined lines with clearly 
defined spacing between the two cells lines. Subsequently the formation of TNTs 
formed between the two separated cell types can be investigated more easily. This 
method of co-cultivation seems to be a promising tool to clarify the structure and 
properties of TNTs formation. It should also clarify, whether TNTs are primary 
products of the cancer cell with damaged mitochondria, or whether they are 
products of donor cells. This method should also shed light on the direction of 
mitochondrial transfer via TNTs, whether it is uni- or bi-directional.  
Total internal reflection fluorescence (TIRF) microscopy can be used to elucidate 
the direction an velocity of the mitochondrial movement through the TNTs. This 
method allows separate mapping of fluorescently labeled structures moving in 
different directions and subsequent evaluation of the direction and speed of their 
motion. Kymographic analysis of mitochondrial transfer will subsequently show if 
the movement of fluorescently labeled mitochondria between the cells is 
unidirectional or bidirectional. The result of kymographic analysis is graphic record 
– kymogram, from which the velocity of moving particles can be calculated.  
Pilot kymographic analysis of data sets obtained by measurement on Nikon Ti-E H-
TIRF microscope examined mitochondrial movement between dsRed labeled MSCs. 
The results showed the approximate velocity of mitochondria of 0.5 μm/s 
(unpublished data by Luděk Štěpánek PhD).  
The co-cultures separated by PDMS microfluidic chip can also be used for 
CLEM/FIB-SEM microscopy analysis of inner arrangement of the tunneling 
nanotube.  
Correlative light-electron microscopy (CLEM) is a method combining fluorescence 
microscopy with electron microscopy. By combining these two methods, the 
information about fluorescence labeled particle is obtained, while the localization 
context of the particle in the internal cell structure is not lost due to subsequent 
electron microscopy analysis (de Boer, Hoogenboom and Giepmans 2015). Various 
ultrastructural techniques are established for 3D-reconstruction of biological 
specimens, however focused ion beam scanning electron microscopy (FIB-SEM) 
allows larger volumes and a higher z-axis resolution is provided,  than by cryo-TEM 
or array tomography (Luckner and Wanner 2018). 
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The preliminary data were obtained by CLEM/FIB-SEM in a homogenous culture of 
MSCs. Mitochondria in living cells were stained with MitoTracker DeepRed (MTDR). 
Tubulin fibers were labeled with SiR-Tubulin. The data obtained by confocal 
microscopy document the co-localization of transported mitochondria and tubulin 
fibers within the TNT structure.  FIB-SEM data correspond with those from the 
confocal microscope, showing 3D-structure of mitochondria in the lumen of TNT. 
Internal mitochondrial structure with cristae was clearly visible in both 
longitudinal- and cross-sections. The FIB-SEM data were acquired by FEI Helios 
NanoLab 660 G3 UC and were combined with the fluorescence microscopy data 
provided by Leica TCS SP8 WLL SMD-FLIM.  
As mentioned in the introduction, TNTs play an important role in the development, 
immune response and in various pathophysiological states. Under physiological 
conditions, TNTs mediate cell contact during the development and play a role in 
stem cell differentiation and repair of damaged tissues. They also participate in 
distant cell communications, and in the exchange of organelles between cells. Under 
pathophysiological conditions, TNTs can have a disease-promoting function, e.g. in 
the restoration of mitochondrial functions in deregulated cancer cells, as discussed 
in the present work. On the other hand, TNTs may have rescuing-functions as 
transporting healthy mitochondria to cells damaged by ischemic reperfusion. 
In vitro evidence exists that intracellular transmission of various signals and cargos 
takes place mediated through TNTs. TNT formation is widespread among a variety 
of cell types. There is no steady opinion on the cytoskeletal nature of TNTs as well 
as on the selectivity of organelles and the direction of their movement in the context 
to cytoskeletal equipment.  
The experimental model described in chapter 5.3.1. documents, intercellular 
mitochondria transport between the acceptor mtDNA depleted cancer cell and the 
donor somatic mesenchymal stem cells. Used advanced imaging could help to 
determine whether the mitochondrial transfer between the two cell types is uni- or 
bi-directional. The transport of mitochondria with depleted mtDNA from cancer 
cells to somatic cells would mean that it is important for cancer cells to ensure a 
more balanced ratio of healthy and non-functional mitochondria to achieve a more 
balanced mitochondrial heteroplasmy. 
Along with a better understanding of the cytoskeletal equipment of TNTs, as well as 
their morphology and internal ordering of the various components they contain, it 
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will be necessary to standardize the terminology in this field of study, to provide a 
broader definition of TNTs and possibly to delineate different subtypes.  
Another and equally important aspect of research in the field of TNTs is, what 
factors are involved in the induction of tunneling nanotubes and to find out the 
biomarker of TNTs will be also beneficial. Different triggering factors as various 
pathogen, metabolic stress, e.g. it seems to be responsible for the TNTs formation.  
For the intercellular transfer of mitochondria, it appears to be one of the key factors 
the production of ROS by the cells that have somehow damaged mitochondria 
(Babenko et al. 2018). In contrast, axonal mitochondrial transport has been shown 
to have a specific deterioration in mitochondrial transport associated with ROS 
production, causing an imbalance in Ca2+ homeostasis and JNK pathway activation 
(Liao, Tandarich and Hollenbeck 2017). Debattisti et al. also investigated 
mitochondrial motility inhibition and found out, that it is induced by physiologically 
relevant doses of H2O2 and is rapidly reversed by removal of H2O2. This supports the 
idea that ROS might work as a physiological regulator of mitochondrial distribution, 
temporally decelerating the organelles when and where it is required (Debattisti et 
al. 2017). Anyway, the nature of ROS is very transient, and it is possible that the TNT 
formation pathway is Akt-dependent and cross-talks with signaling complexes from 
the lysosome and the mitochondria. Increased oxidative stress, through increased 
ROS formation from aggregates within the cytosol or from lysosomal aggregation of 
protein, can cause mitochondrial dysfunction and lysosomal dysfunction, which act 
in a feedback loop to create increased ROS, which are believed to be responsible for 
TNT formation through the Akt pathway (Rustom 2016, Victoria and Zurzolo 2017). 
Next research can also target the regulation, induction and suppression of TNTs 
production and use TNTs in therapy, or on the contrary, synthesize inhibitors of key 
TNT-drivers. One of the possible uses for therapeutic purposes would be also the 
targeted delivery of drugs to damaged cells through TNTs. 
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7. Conclusion 
Restoration of mtDNA mediated by the transfer of intact mitochondria was 
confirmed in B16 rho0 cells stably expressing BFP in nuclei, s.c. injected into 
C57BL/6Nsu9DsRed2 mice. Subsequent analysis of the formed pre-tumour lesions 
excised 11 days later, confirmed the presence of dsRed fluorescent host cell 
mitochondria in the recipient B16 rho0 cells expressing BFP in nuclei. Further 
analysis of the established sub-line (B16 rho0 DP cells) confirmed a comparable 
metabolic state as in the parental B16 cells and STED microscopy analysis 
documented  a similar distribution of mitochondrial nucleoids in both B16 
counterparts. The B16 rho0 DP cells formed tumours with a similar efficacy as the 
parental B16 cells.  
Analogous results were obtained with the 4T1 cell line. Additionally, tumours 
derived from 4T1 rho0 cells were excised in defined time points and analysed 
subsequently for the aspects of metabolic state and mtDNA content as well as for the 
proliferation rate. The results document gradual increase in ATP production 
mediated by OXPHOS. The measured NADH/NAD+ ratios also confirmed the 
recovery of the parental phenotype in the 4T1 rho0 D15-D60 sub-lines. These data 
are in accordance with the increasing levels of mtDNA in the analysed 4T1 sub-lines, 
observed by STED microscopy as well as with the increasing cell proliferation rates 
estimated by the Ki-67 test.  
Microscopy experiments focused on intercellular mitochondrial transfer between 
mtDNA depleted cancer cells and mice derived MSCs mediated by TNTs brought 
interesting results as well as a lot of questions. The data obtained by confocal 
microscopy proved the formation of TNTs between the two cell types and transfer 
of mitochondria from MSCs into 4T1 rho0 cells. Presence of alpha-tubulin in TNTs 
and its co-localization with donor cell mitochondria was also documented. 
Future direction of this research will include CLEM/FIB-SEM microscopy and TIRF 
microscopy and will benefit from the use of the PDMS microfluidic device.  
This approach will help to understand the nature of TNTs and the principles of the 
mediated mitochondrial transfer.   
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